false false 2019-09-30 Q3 Q3 0001578845 0001620602 --12-31 --12-31 Large Accelerated Filer Non-accelerated Filer Yes Yes Yes Yes P1Y P1Y 0.017 0.18 0.022 0.029 P7Y P7Y P1Y7M6D P1Y7M6D 2013 2014 2015 2016 2010 2011 2012 2013 2010 2011 2012 2013 2014 2009 2010 2011 2012 2013 2014 P4Y4M24D P4Y4M24D P4Y0M0D P4Y0M0D 0001578845 2019-01-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember 2019-01-01 2019-09-30 xbrli:shares 0001578845 2019-11-01 0001578845 agn:WarnerChilcottLimitedMember 2019-11-01 iso4217:USD 0001578845 2019-09-30 0001578845 2018-12-31 iso4217:USD xbrli:shares 0001578845 2019-07-01 2019-09-30 0001578845 2018-07-01 2018-09-30 0001578845 2018-01-01 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-09-30 0001578845 2017-12-31 0001578845 2018-09-30 0001578845 us-gaap:CommonStockMember 2017-12-31 0001578845 us-gaap:PreferredStockMember 2017-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001578845 us-gaap:RetainedEarningsMember 2017-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2017-12-31 0001578845 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001578845 2018-01-01 2018-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001578845 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001578845 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001578845 us-gaap:CommonStockMember 2018-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001578845 us-gaap:RetainedEarningsMember 2018-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-03-31 0001578845 2018-03-31 0001578845 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001578845 2018-04-01 2018-06-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001578845 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001578845 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0001578845 us-gaap:CommonStockMember 2018-06-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001578845 us-gaap:RetainedEarningsMember 2018-06-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001578845 us-gaap:NoncontrollingInterestMember 2018-06-30 0001578845 2018-06-30 0001578845 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001578845 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001578845 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0001578845 us-gaap:CommonStockMember 2018-09-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001578845 us-gaap:RetainedEarningsMember 2018-09-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001578845 us-gaap:NoncontrollingInterestMember 2018-09-30 0001578845 us-gaap:CommonStockMember 2018-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2018-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001578845 2019-01-01 2019-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001578845 us-gaap:RetainedEarningsMember 2019-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-03-31 0001578845 2019-03-31 0001578845 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001578845 2019-04-01 2019-06-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001578845 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001578845 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001578845 us-gaap:CommonStockMember 2019-06-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001578845 us-gaap:RetainedEarningsMember 2019-06-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001578845 us-gaap:NoncontrollingInterestMember 2019-06-30 0001578845 2019-06-30 0001578845 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001578845 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001578845 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0001578845 us-gaap:CommonStockMember 2019-09-30 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001578845 us-gaap:RetainedEarningsMember 2019-09-30 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001578845 us-gaap:NoncontrollingInterestMember 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-07-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember 2018-07-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember 2018-01-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember 2018-01-01 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember 2018-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember 2018-04-01 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember 2018-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember 2019-04-01 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-04-01 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember 2019-06-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-07-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-09-30 0001578845 agn:WarnerChilcottAcquisitionMember 2019-01-01 2019-09-30 agn:Country 0001578845 agn:AbbVieIncMember 2019-06-25 0001578845 agn:AbbVieIncMember 2019-06-24 2019-06-25 0001578845 agn:AbbVieIncMember us-gaap:SubsequentEventMember 2019-10-25 0001578845 agn:AbbVieIncMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-09-30 0001578845 us-gaap:MaterialReconcilingItemsMember 2018-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-07-01 2019-09-30 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-09-30 0001578845 us-gaap:MaterialReconcilingItemsMember 2018-07-01 2018-09-30 0001578845 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-09-30 0001578845 us-gaap:RealEstateMember 2019-01-01 0001578845 agn:FleetMember 2019-01-01 0001578845 agn:OtherMember 2019-01-01 0001578845 2019-01-01 0001578845 us-gaap:AccountingStandardsUpdate201602Member srt:RestatementAdjustmentMember 2019-01-01 2019-01-01 0001578845 agn:ChargebacksMember 2018-12-31 0001578845 agn:RebatesMember 2018-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2018-12-31 0001578845 agn:CashDiscountsMember 2018-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2018-12-31 0001578845 agn:ChargebacksMember 2019-01-01 2019-09-30 0001578845 agn:RebatesMember 2019-01-01 2019-09-30 0001578845 agn:ReturnsAndOtherAllowancesMember 2019-01-01 2019-09-30 0001578845 agn:CashDiscountsMember 2019-01-01 2019-09-30 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2019-01-01 2019-09-30 0001578845 agn:ChargebacksMember 2019-09-30 0001578845 agn:RebatesMember 2019-09-30 0001578845 agn:ReturnsAndOtherAllowancesMember 2019-09-30 0001578845 agn:CashDiscountsMember 2019-09-30 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2019-09-30 0001578845 us-gaap:ProductMember 2019-07-01 2019-09-30 0001578845 us-gaap:ProductMember 2018-07-01 2018-09-30 0001578845 us-gaap:ProductMember 2019-01-01 2019-09-30 0001578845 us-gaap:ProductMember 2018-01-01 2018-09-30 xbrli:pure 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001578845 agn:StockAwardsMember 2019-07-01 2019-09-30 0001578845 agn:StockAwardsMember 2019-01-01 2019-09-30 0001578845 agn:StockAwardsMember 2018-07-01 2018-09-30 0001578845 agn:StockAwardsMember 2018-01-01 2018-09-30 0001578845 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001578845 agn:EnvyMedicalIncMember 2019-03-26 2019-03-26 0001578845 agn:EnvyMedicalIncMember 2019-03-26 0001578845 2019-01-01 2019-06-30 0001578845 agn:TevaMember 2018-01-01 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:SettlementOfInitialAcceleratedShareRepurchaseMember 2018-03-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:SettlementOfForwardSaleMember 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:OpenMarketSalesMember 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:SettlementOfInitialAcceleratedShareRepurchaseMember 2018-01-01 2018-03-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:SettlementOfForwardSaleMember 2018-01-01 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember agn:OpenMarketSalesMember 2018-01-01 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-01 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2017-01-01 2017-12-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 2018-03-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember us-gaap:AccountingStandardsUpdate201601Member 2018-03-31 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-09-30 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-01-17 0001578845 agn:TevaPharmaceuticalIndustriesLtdMember 2018-05-07 0001578845 agn:NonStrategicAssetGroupMember 2018-09-30 0001578845 agn:NonStrategicAssetGroupMember 2018-01-01 2018-09-30 0001578845 agn:AlmirallSAMember 2018-07-01 2018-09-30 0001578845 agn:AlmirallSAMember 2018-01-01 2018-09-30 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-01-01 2019-09-30 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-01-01 2019-09-30 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-01-01 2019-09-30 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-09-30 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-09-30 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-09-30 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-07-01 2018-09-30 0001578845 agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2018-07-01 2018-09-30 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2018-07-01 2018-09-30 0001578845 agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2018-07-01 2018-09-30 0001578845 agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2018-07-01 2018-09-30 0001578845 agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2018-07-01 2018-09-30 0001578845 agn:TwoPointFourFivePercentageSeniorNotesDueJuneFifteenTwoThousandAndNineteenMember 2018-01-01 2018-09-30 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-01-01 2018-09-30 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2018-01-01 2018-09-30 0001578845 agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2018-01-01 2018-09-30 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2018-01-01 2018-09-30 0001578845 agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2018-01-01 2018-09-30 0001578845 agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2018-01-01 2018-09-30 0001578845 agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2018-01-01 2018-09-30 0001578845 agn:TwoPointFourFivePercentageSeniorNotesDueJuneFifteenTwoThousandAndNineteenMember 2018-09-30 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-09-30 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2018-09-30 0001578845 agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2018-09-30 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2018-09-30 0001578845 agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2018-09-30 0001578845 agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2018-09-30 0001578845 agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2018-09-30 0001578845 agn:TwoThousandNineteenGrantsMember srt:MinimumMember 2019-01-01 2019-09-30 0001578845 agn:TwoThousandEighteenGrantsMember srt:MinimumMember 2018-01-01 2018-09-30 0001578845 agn:TwoThousandNineteenGrantsMember srt:MaximumMember 2019-01-01 2019-09-30 0001578845 agn:TwoThousandNineteenGrantsMember 2019-01-01 2019-09-30 0001578845 agn:TwoThousandEighteenGrantsMember 2018-01-01 2018-09-30 0001578845 agn:EquityBasedCompensationAwardsMember 2019-07-01 2019-09-30 0001578845 agn:EquityBasedCompensationAwardsMember 2018-07-01 2018-09-30 0001578845 agn:EquityBasedCompensationAwardsMember 2019-01-01 2019-09-30 0001578845 agn:EquityBasedCompensationAwardsMember 2018-01-01 2018-09-30 0001578845 us-gaap:RestrictedStockMember 2018-12-31 0001578845 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001578845 us-gaap:RestrictedStockMember 2019-09-30 0001578845 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001578845 agn:NonQualifiedOptionsMember 2018-12-31 0001578845 agn:NonQualifiedOptionsMember 2019-01-01 2019-09-30 0001578845 agn:NonQualifiedOptionsMember 2019-09-30 0001578845 agn:NonQualifiedOptionsMember 2018-01-01 2018-12-31 agn:Segment 0001578845 us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0001578845 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0001578845 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-07-01 2018-09-30 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-07-01 2018-09-30 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-07-01 2018-09-30 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-07-01 2018-09-30 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-07-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-07-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-07-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:VraylarMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:ZenpepMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:SaphrisMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:TeflaroMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:NamzaricMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:AvycazMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:SavellaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:AczoneMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:AczoneMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:NamendaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:LilettaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:DalvanceMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USSpecializedTherapeuticsMember agn:OtherMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:USGeneralMedicineMember agn:OtherMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:InternationalMember agn:OtherMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2018-01-01 2018-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2018-01-01 2018-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2018-01-01 2018-09-30 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0001578845 srt:RestatementAdjustmentMember 2019-01-01 2019-09-30 0001578845 srt:RestatementAdjustmentMember 2019-07-24 2019-07-24 0001578845 us-gaap:InventoryValuationReserveMember agn:BiocellMember 2019-01-01 2019-09-30 0001578845 agn:USSpecializedTherapeuticsMember 2018-12-31 0001578845 agn:USGeneralMedicineMember 2018-12-31 0001578845 agn:InternationalMember 2018-12-31 0001578845 agn:USSpecializedTherapeuticsMember 2019-01-01 2019-09-30 0001578845 agn:USGeneralMedicineMember 2019-01-01 2019-09-30 0001578845 agn:InternationalMember 2019-01-01 2019-09-30 0001578845 agn:USSpecializedTherapeuticsMember 2019-09-30 0001578845 agn:USGeneralMedicineMember 2019-09-30 0001578845 agn:InternationalMember 2019-09-30 0001578845 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2019-01-01 2019-09-30 0001578845 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2019-01-01 2019-09-30 0001578845 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2018-01-01 2018-12-31 0001578845 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2018-01-01 2018-12-31 0001578845 agn:USGeneralMedicineMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember 2019-06-29 2019-06-30 0001578845 agn:USSpecializedTherapeuticsMember agn:USEyeCareReportingUnitMember 2019-06-30 0001578845 agn:USSpecializedTherapeuticsMember agn:USMedicalAestheticsReportingUnitMember 2019-06-30 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2018-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2018-12-31 0001578845 agn:CostBasisMember 2018-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2019-01-01 2019-09-30 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2019-01-01 2019-09-30 0001578845 agn:CostBasisMember 2019-01-01 2019-09-30 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2019-09-30 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2019-09-30 0001578845 agn:CostBasisMember 2019-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2018-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2019-01-01 2019-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2019-09-30 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2018-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2018-12-31 0001578845 agn:AccumulatedAmortizationMember 2018-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2019-01-01 2019-09-30 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2019-01-01 2019-09-30 0001578845 agn:AccumulatedAmortizationMember 2019-01-01 2019-09-30 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2019-09-30 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2019-09-30 0001578845 agn:AccumulatedAmortizationMember 2019-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:FacialAestheticsMember 2019-01-01 2019-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:TobiraTherapeuticsIncMember agn:GIProjectMember 2019-01-01 2019-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember 2019-01-01 2019-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:EyeCareProjectMember agn:ChangesInLaunchPlansMember 2018-01-01 2018-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:VitaePharmaceuticalsIncMember agn:DelayInClinicalStudiesMember 2018-01-01 2018-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:DermatologyProjectMember agn:DelayInClinicalStudiesMember 2018-01-01 2018-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:EyeCareProjectMember 2018-01-01 2018-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:CentralNervousSystemMember agn:DelayInClinicalStudiesMember 2018-01-01 2018-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:AllerganIncMember agn:EyeCareProjectMember agn:DelayInClinicalStudiesMember 2018-01-01 2018-09-30 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:VitaePharmaceuticalsIncMember agn:RORytMember 2018-01-01 2018-03-31 0001578845 agn:AlmirallSAMember 2018-09-30 0001578845 agn:ProductRightsAndOtherRelatedIntangiblesMember 2019-09-30 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-09-30 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-12-31 0001578845 agn:FloatingRateNotesMember 2019-09-30 0001578845 agn:FloatingRateNotesMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2018-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2018-12-31 0001578845 agn:FixedRateNotesMember 2019-09-30 0001578845 agn:FixedRateNotesMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2018-12-31 0001578845 agn:EuroDenominatedNotesMember 2019-09-30 0001578845 agn:EuroDenominatedNotesMember 2018-12-31 0001578845 agn:OtherDebtMember 2019-09-30 0001578845 agn:OtherDebtMember 2018-12-31 0001578845 agn:CapitalLeaseMember 2018-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2019-01-01 2019-09-30 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2019-01-01 2019-09-30 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2019-01-01 2019-09-30 0001578845 agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember agn:FloatingRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember agn:FixedRateNotesMember 2018-01-01 2018-12-31 0001578845 agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember agn:EuroDenominatedNotesMember 2018-01-01 2018-12-31 0001578845 agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember agn:EuroDenominatedNotesMember 2018-01-01 2018-12-31 0001578845 agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember agn:EuroDenominatedNotesMember 2018-01-01 2018-12-31 0001578845 agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember agn:EuroDenominatedNotesMember 2018-01-01 2018-12-31 0001578845 agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember agn:EuroDenominatedNotesMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2018-01-01 2018-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2018-01-01 2018-12-31 0001578845 us-gaap:SeniorNotesMember 2019-09-30 iso4217:EUR 0001578845 agn:FloatingRateNotesMember 2019-01-01 2019-09-30 0001578845 srt:MinimumMember 2019-01-01 2019-09-30 0001578845 srt:MaximumMember 2019-01-01 2019-09-30 0001578845 us-gaap:RealEstateMember srt:MinimumMember 2019-01-01 2019-09-30 0001578845 us-gaap:RealEstateMember srt:MaximumMember 2019-01-01 2019-09-30 0001578845 us-gaap:RealEstateMember 2019-09-30 0001578845 agn:FleetSubjectToOperatingLeaseMember 2019-09-30 0001578845 agn:OtherThanRealEstateAndFleetMember 2019-09-30 0001578845 us-gaap:PropertySubjectToOperatingLeaseMember 2018-01-01 2018-12-31 0001578845 agn:FleetSubjectToOperatingLeaseMember 2018-01-01 2018-12-31 0001578845 us-gaap:DomesticCountryMember 2019-01-01 2019-09-30 0001578845 agn:NamendaMember 2019-01-01 2019-09-30 0001578845 us-gaap:DomesticCountryMember 2018-01-01 2018-09-30 0001578845 agn:MedicalDermatologyMember 2018-01-01 2018-09-30 0001578845 agn:AllerganWCHoldingIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-09-30 0001578845 agn:WarnerChilcottCorporationMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-09-30 0001578845 agn:ForestLaboratoriesIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-09-30 0001578845 agn:AllerganIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-09-30 0001578845 agn:JulyTwentySixTwoThousandEighteenShareRepurchaseProgramMember 2019-09-30 0001578845 2018-03-01 0001578845 us-gaap:CommonStockMember 2018-02-28 2018-03-01 0001578845 us-gaap:ForwardContractsMember 2018-11-30 0001578845 2018-11-01 2018-11-30 0001578845 2018-11-30 0001578845 us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-09-30 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-01 2019-01-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-09-30 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-01 2019-09-30 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-07-01 2019-09-30 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-09-30 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2018-07-01 2018-09-30 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001578845 srt:MaximumMember 2018-01-01 2018-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001578845 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001578845 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0001578845 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001578845 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001578845 agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:ContingentConsiderationObligationMember 2017-12-31 0001578845 agn:ContingentConsiderationObligationMember 2018-01-01 2018-09-30 0001578845 agn:ContingentConsiderationObligationMember 2018-09-30 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2019-01-01 2019-09-30 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2019-09-30 0001578845 us-gaap:ShortTermInvestmentsMember 2019-09-30 0001578845 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001578845 agn:SeveranceMember 2018-12-31 0001578845 us-gaap:OtherRestructuringMember 2018-12-31 0001578845 us-gaap:CostOfSalesMember agn:SeveranceMember 2019-01-01 2019-09-30 0001578845 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0001578845 us-gaap:SellingAndMarketingExpenseMember agn:SeveranceMember 2019-01-01 2019-09-30 0001578845 us-gaap:SellingAndMarketingExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0001578845 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember agn:SeveranceMember 2019-01-01 2019-09-30 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0001578845 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001578845 agn:SeveranceMember 2019-01-01 2019-09-30 0001578845 us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0001578845 agn:SeveranceMember 2019-09-30 0001578845 us-gaap:OtherRestructuringMember 2019-09-30 0001578845 agn:SandozIncorporationMember us-gaap:PendingLitigationMember 2018-08-01 2018-08-01 0001578845 agn:PrinstonMember 2019-01-01 2019-09-30 0001578845 agn:SlaybackMember 2019-01-01 2019-09-30 0001578845 agn:SunAndSunCertainAffiliatesMember 2019-01-01 2019-09-30 0001578845 agn:AurobindoMember 2019-01-01 2019-09-30 0001578845 agn:MylanMember 2019-01-01 2019-09-30 0001578845 agn:DevaMember 2019-01-01 2019-09-30 0001578845 agn:ArgentumMember agn:RestasisMember 2019-01-01 2019-09-30 0001578845 agn:KBCMediaRelationsLimitedLiabilityCompanyMember agn:JuvedermMember 2019-01-01 2019-09-30 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2019-01-01 2019-09-30 agn:Trademark 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2019-09-30 agn:Cases 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember 2019-01-01 2019-09-30 0001578845 agn:ProductLiabilityLitigationMember us-gaap:PendingLitigationMember country:CA 2019-09-30 0001578845 agn:ProductLiabilityLitigationMember us-gaap:PendingLitigationMember 2019-01-01 2019-09-30 0001578845 agn:ProductLiabilityLitigationMember agn:BreastImplantLitigationMember country:CA 2019-01-01 2019-09-30 0001578845 agn:ProductLiabilityLitigationMember agn:BreastImplantLitigationMember country:US 2019-01-01 2019-09-30 agn:Defendant 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember agn:CelexaLexaproLitigationMember 2019-01-01 2019-09-30 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember agn:RepliFormLitigationMember 2019-01-01 2019-09-30 0001578845 agn:ProductLiabilityLitigationMember agn:RepliFormLitigationMember 2019-09-30 agn:Product 0001578845 agn:BotoxMember 2015-12-27 2015-12-28 agn:Patent 0001578845 agn:SaintRegisMohawkTribeMember agn:RestasisMember 2015-12-28 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-09-30 0001578845 agn:AllerganCapitalSarlMember 2019-09-30 0001578845 agn:NonGuarantorsMember 2019-09-30 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-09-30 0001578845 srt:ConsolidationEliminationsMember 2019-09-30 0001578845 agn:AllerganFundingScsMember 2019-09-30 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-12-31 0001578845 agn:AllerganCapitalSarlMember 2018-12-31 0001578845 agn:AllerganFundingScsMember 2018-12-31 0001578845 agn:NonGuarantorsMember 2018-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2018-12-31 0001578845 srt:ConsolidationEliminationsMember 2018-12-31 0001578845 agn:NonGuarantorsMember 2019-07-01 2019-09-30 0001578845 agn:AllerganCapitalSarlMember 2019-07-01 2019-09-30 0001578845 agn:AllerganFundingScsMember 2019-07-01 2019-09-30 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-07-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-07-01 2019-09-30 0001578845 srt:ConsolidationEliminationsMember 2019-07-01 2019-09-30 0001578845 agn:NonGuarantorsMember 2019-01-01 2019-09-30 0001578845 agn:AllerganCapitalSarlMember 2019-01-01 2019-09-30 0001578845 agn:AllerganFundingScsMember 2019-01-01 2019-09-30 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-01-01 2019-09-30 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-01-01 2019-09-30 0001578845 srt:ConsolidationEliminationsMember 2019-01-01 2019-09-30 0001578845 agn:NonGuarantorsMember 2018-07-01 2018-09-30 0001578845 agn:AllerganFundingScsMember 2018-07-01 2018-09-30 0001578845 agn:AllerganCapitalSarlMember 2018-07-01 2018-09-30 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2018-07-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-07-01 2018-09-30 0001578845 srt:ConsolidationEliminationsMember 2018-07-01 2018-09-30 0001578845 agn:NonGuarantorsMember 2018-01-01 2018-09-30 0001578845 agn:AllerganFundingScsMember 2018-01-01 2018-09-30 0001578845 agn:AllerganCapitalSarlMember 2018-01-01 2018-09-30 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2018-01-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-01-01 2018-09-30 0001578845 srt:ConsolidationEliminationsMember 2018-01-01 2018-09-30 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2017-12-31 0001578845 agn:AllerganCapitalSarlMember 2017-12-31 0001578845 agn:AllerganFundingScsMember 2017-12-31 0001578845 agn:NonGuarantorsMember 2017-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-09-30 0001578845 agn:AllerganCapitalSarlMember 2018-09-30 0001578845 agn:AllerganFundingScsMember 2018-09-30 0001578845 agn:NonGuarantorsMember 2018-09-30

false false 2020-03-31 Q1 Q1 0001578845 0001620602 --12-31 --12-31 Large Accelerated Filer Non-accelerated Filer Yes Yes Yes Yes 1 1 0.017 0.235 0.019 P7Y 0.022 0.264 0.026 P1Y4M24D P1Y10M24D P3Y10M24D P3Y10M24D 2013 2014 2015 2016 2017 2010 2011 2012 2013 2010 2011 2012 2013 2014 2009 2010 2011 2012 2013 2014 0001578845 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember 2020-01-01 2020-03-31 0001578845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001578845 agn:FloatingRateNotesDue2020Member 2020-01-01 2020-03-31 0001578845 agn:ZeroPointFiveZeroZeroPercentageNotesDueTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:OnePointFiveZeroZeroPercentageNotesDueTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001578845 agn:OnePointTwoFiveZeroPercentageNotesDueTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001578845 agn:TwoPointSixTwoFivePercentageNotesDueTwoThousandTwentyEightMember 2020-01-01 2020-03-31 0001578845 agn:TwoPointOneTwoFivePercentageNotesDueTwoThousandTwentyNineMember 2020-01-01 2020-03-31 xbrli:shares 0001578845 2020-05-01 0001578845 agn:WarnerChilcottLimitedMember 2020-05-01 iso4217:USD 0001578845 2020-03-31 0001578845 2019-12-31 iso4217:USD xbrli:shares 0001578845 2019-01-01 2019-03-31 0001578845 2018-12-31 0001578845 2019-03-31 0001578845 us-gaap:CommonStockMember 2018-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2018-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001578845 us-gaap:RetainedEarningsMember 2019-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-03-31 0001578845 us-gaap:CommonStockMember 2019-12-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001578845 us-gaap:RetainedEarningsMember 2019-12-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001578845 us-gaap:NoncontrollingInterestMember 2019-12-31 0001578845 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001578845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001578845 us-gaap:CommonStockMember 2020-03-31 0001578845 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001578845 us-gaap:RetainedEarningsMember 2020-03-31 0001578845 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001578845 us-gaap:NoncontrollingInterestMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:MemberUnitsMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:RetainedEarningsMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedMember us-gaap:NoncontrollingInterestMember 2020-03-31 agn:Country 0001578845 agn:AbbVieIncMember 2019-06-25 0001578845 agn:AbbVieIncMember 2019-06-24 2019-06-25 0001578845 agn:AbbVieIncMember 2019-10-25 0001578845 agn:AbbVieIncMember 2019-10-25 2019-10-25 0001578845 us-gaap:MaterialReconcilingItemsMember 2020-03-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-12-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0001578845 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0001578845 agn:ChargebacksMember 2019-12-31 0001578845 agn:RebatesMember 2019-12-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2019-12-31 0001578845 agn:CashDiscountsMember 2019-12-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2019-12-31 0001578845 agn:ChargebacksMember 2020-01-01 2020-03-31 0001578845 agn:RebatesMember 2020-01-01 2020-03-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2020-01-01 2020-03-31 0001578845 agn:CashDiscountsMember 2020-01-01 2020-03-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2020-01-01 2020-03-31 0001578845 agn:ChargebacksMember 2020-03-31 0001578845 agn:RebatesMember 2020-03-31 0001578845 agn:ReturnsAndOtherAllowancesMember 2020-03-31 0001578845 agn:CashDiscountsMember 2020-03-31 0001578845 us-gaap:SalesReturnsAndAllowancesMember 2020-03-31 0001578845 us-gaap:ProductMember 2020-01-01 2020-03-31 0001578845 us-gaap:ProductMember 2019-01-01 2019-03-31 xbrli:pure 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001578845 us-gaap:AccountingStandardsUpdate201409Member us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001578845 agn:StockAwardsMember 2020-01-01 2020-03-31 0001578845 agn:TwoThousandNineteenGrantsMember srt:MinimumMember 2020-01-01 2020-03-31 0001578845 agn:TwoThousandNineteenGrantsMember srt:MaximumMember 2020-01-01 2020-03-31 0001578845 agn:TwoThousandNineteenGrantsMember 2020-01-01 2020-03-31 0001578845 agn:EquityBasedCompensationAwardsMember 2020-01-01 2020-03-31 0001578845 agn:EquityBasedCompensationAwardsMember 2019-01-01 2019-03-31 0001578845 us-gaap:RestrictedStockMember 2019-12-31 0001578845 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001578845 us-gaap:RestrictedStockMember 2020-03-31 0001578845 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001578845 agn:NonQualifiedOptionsMember 2019-12-31 0001578845 agn:NonQualifiedOptionsMember 2020-01-01 2020-03-31 0001578845 agn:NonQualifiedOptionsMember 2020-03-31 0001578845 agn:NonQualifiedOptionsMember 2019-01-01 2019-12-31 agn:Segment 0001578845 us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 srt:EuropeMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:AsiaPacificMiddleEastAndAfricaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:LatinAmericaAndCanadaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:OtherGeographicAreaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2019-01-01 2019-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:UbrelvyMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:UbrelvyMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USSpecializedTherapeuticsMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:USGeneralMedicineMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:BotoxMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:JuvedermCollectionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:RestasisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LinzessAndConstellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:VraylarMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:VraylarMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LumiganAndGanfortMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:BystolicAndByvalsonMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LoLoestrinFeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AlphaganAndCombiganMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:EyeDropsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AllodermMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:OzurdexMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ViibrydFetzimaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:BreastImplantsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CoolsculptingConsumablesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ZenpepMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ZenpepMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CarafateAndSulcrateMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ArmourThyroidMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:ViberziMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:SkinCareMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:DelzicolAndAsacolHDMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:TeflaroMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:SaphrisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:SaphrisMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:AvycazMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AvycazMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CoolsculptingSystemsAndAddOnApplicatorsMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:NamzaricMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:NamzaricMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:SavellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:SavellaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:LilettaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:LilettaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:CanasaAndSalofalkMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:RapafloMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:DalvanceMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:DalvanceMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:NamendaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:NamendaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:KybellaAndBelkyraMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:AczoneMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:AczoneMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USGeneralMedicineMember agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:InternationalMember agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:OtherMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001578845 agn:USSpecializedTherapeuticsMember 2019-12-31 0001578845 agn:USGeneralMedicineMember 2019-12-31 0001578845 agn:InternationalMember 2019-12-31 0001578845 agn:InternationalMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember 2020-03-31 0001578845 agn:USGeneralMedicineMember 2020-03-31 0001578845 agn:InternationalMember 2020-03-31 0001578845 country:US srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2020-01-01 2020-03-31 0001578845 agn:InternationalMember srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2020-01-01 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:USEyeCareReportingUnitMember 2020-03-31 0001578845 agn:USSpecializedTherapeuticsMember agn:USMedicalAestheticsReportingUnitMember 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2019-12-31 0001578845 agn:CostBasisMember 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:CostBasisMember 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:CostBasisMember 2020-03-31 0001578845 agn:CostBasisMember 2020-03-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2019-12-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2020-01-01 2020-03-31 0001578845 agn:IndefiniteInProcessResearchAndDevelopmentMember agn:CostBasisMember 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2019-12-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2019-12-31 0001578845 agn:AccumulatedAmortizationMember 2019-12-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2020-01-01 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2020-01-01 2020-03-31 0001578845 agn:AccumulatedAmortizationMember 2020-01-01 2020-03-31 0001578845 agn:ProductRightsAndOtherIntangiblesMember agn:AccumulatedAmortizationMember 2020-03-31 0001578845 us-gaap:TradeNamesMember agn:AccumulatedAmortizationMember 2020-03-31 0001578845 agn:AccumulatedAmortizationMember 2020-03-31 0001578845 agn:KybellaMember agn:NonAnnualTestingMember 2020-01-01 2020-03-31 0001578845 agn:ProductRightsAndOtherRelatedIntangiblesMember 2020-03-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:FloatingRateNotesMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2019-12-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2019-12-31 0001578845 agn:FixedRateNotesMember 2020-03-31 0001578845 agn:FixedRateNotesMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2019-12-31 0001578845 agn:EuroDenominatedNotesMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember 2019-12-31 0001578845 agn:OtherDebtMember 2020-03-31 0001578845 agn:OtherDebtMember 2019-12-31 0001578845 agn:FloatingRateNotesMember agn:SeniorNotesDueMarchTwelveTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointThreeSevenFivePercentageSeniorNotesDueSeptemberFifteenTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightSevenFivePercentageSeniorNotesDueFebruaryFifteenTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FivePointZeroZeroZeroPercentageSeniorNotesDueDecemberFifteenTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointFourFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyTwoMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointTwoFiveZeroPercentageSeniorNotesDueOctoberOneTwoThousandTwentyTwoMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:TwoPointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:ThreePointEightZeroZeroPercentageSeniorNotesDueMarchFifteenTwoThousandTwentyFiveMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointFiveFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandThirtyFiveMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSixTwoFivePercentageSeniorNotesDueOctoberOneTwoThousandFortyTwoMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointEightFivePercentageSeniorNotesDueJuneFifteenTwoThousandFortyFourMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember agn:FourPointSevenFiveZeroPercentageSeniorNotesDueMarchFifteenTwoThousandFortyFiveMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueJuneOneTwoThousandNineteenMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:ZeroPointFiveZeroZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyOneMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointFiveZeroZeroPercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:OnePointTwoFiveZeroPercentageSeniorNotesDueJuneOneTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointSixTwoFivePercentageSeniorNotesDueNovemberFifteenTwoThousandTwentyEightMember 2020-01-01 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:TwoPointOneTwoFivePercentageSeniorNotesDueJuneOneTwoThousandTwentyNineMember 2020-01-01 2020-03-31 0001578845 agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember agn:FloatingRateNotesMember 2020-01-01 2020-03-31 0001578845 agn:ThreePointZeroZeroZeroPercentageSeniorNotesDueMarchTwelveTwoThousandTwentyMember agn:FixedRateNotesMember 2020-03-31 0001578845 agn:EuroDenominatedNotesMember agn:SeniorNotesDueNovemberFifteenTwoThousandTwentyMember 2020-01-01 2020-03-31 0001578845 agn:FloatingRateNotesMember 2020-01-01 2020-03-31 0001578845 agn:FixedRateNotesMember 2020-01-01 2020-03-31 0001578845 us-gaap:DomesticCountryMember 2019-01-01 2019-03-31 0001578845 agn:AllerganWCHoldingIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:AllerganPharmaIncSubsidiariesMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottCorporationMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:ForestLaboratoriesIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 agn:AllerganIncMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2019-01-01 2019-01-31 0001578845 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-03-31 0001578845 us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001578845 srt:MaximumMember 2020-01-01 2020-03-31 0001578845 srt:MaximumMember 2019-01-01 2019-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001578845 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001578845 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001578845 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001578845 agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:ContingentConsiderationObligationMember 2018-12-31 0001578845 agn:ContingentConsiderationObligationMember 2019-01-01 2019-03-31 0001578845 agn:ContingentConsiderationObligationMember 2019-03-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2019-12-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2020-01-01 2020-03-31 0001578845 agn:TobiraTherapeuticsIncMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:MedicinesThreeSixZeroMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:AqueSysAcquisitionMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:OculeveAcquisitionMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:ForSightMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:ForestLaboratoriesIncMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:OtherAcquisitionMember agn:ContingentConsiderationObligationMember 2020-03-31 0001578845 agn:BystolicMember agn:AjantaMember 2020-01-01 2020-03-31 0001578845 agn:SandozIncorporationMember us-gaap:PendingLitigationMember 2018-08-01 2018-08-01 0001578845 agn:PrinstonMember 2020-01-01 2020-03-31 0001578845 agn:SunAndSunCertainAffiliatesMember 2020-01-01 2020-03-31 0001578845 agn:AurobindoMember 2020-01-01 2020-03-31 0001578845 agn:MylanMember 2020-01-01 2020-03-31 0001578845 agn:KBCMediaRelationsLimitedLiabilityCompanyMember agn:JuvedermMember 2020-01-01 2020-03-31 iso4217:EUR 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2020-01-01 2020-03-31 agn:Trademark 0001578845 agn:DermavitaLimitedPartnershipMember srt:MinimumMember 2020-03-31 0001578845 agn:LoestrinTwentyFourLitigationMember 2020-03-31 0001578845 agn:NamendaLitigationMember 2020-01-01 2020-03-31 agn:Claim 0001578845 agn:WarnerChilcottMarketingPracticesMember agn:WarnerChilcottLimitedMember 2020-01-01 2020-03-31 agn:Plaintiff 0001578845 agn:GenericDrugPricingSecuritiesLitigationMember stpr:NJ 2020-01-01 2020-03-31 agn:Defendant 0001578845 agn:PrescriptionDrugAbuseLitigationMember us-gaap:PendingLitigationMember 2020-03-31 agn:Cases 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember us-gaap:PendingLitigationMember country:CA 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember us-gaap:PendingLitigationMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember agn:BreastImplantLitigationMember country:CA srt:MinimumMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember agn:CelexaLexaproLitigationMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember srt:MinimumMember agn:RepliFormLitigationMember 2020-01-01 2020-03-31 0001578845 agn:ProductLiabilityLitigationMember agn:RepliFormLitigationMember 2020-03-31 agn:Product 0001578845 agn:BotoxMember 2015-12-27 2015-12-28 agn:Patent 0001578845 agn:SaintRegisMohawkTribeMember agn:RestasisMember 2015-12-28 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2020-03-31 0001578845 agn:AllerganCapitalSarlMember 2020-03-31 0001578845 agn:AllerganFundingScsMember 2020-03-31 0001578845 agn:NonGuarantorsMember 2020-03-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2020-03-31 0001578845 srt:ConsolidationEliminationsMember 2020-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-12-31 0001578845 agn:AllerganCapitalSarlMember 2019-12-31 0001578845 agn:AllerganFundingScsMember 2019-12-31 0001578845 agn:NonGuarantorsMember 2019-12-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-12-31 0001578845 srt:ConsolidationEliminationsMember 2019-12-31 0001578845 agn:NonGuarantorsMember 2020-01-01 2020-03-31 0001578845 agn:AllerganCapitalSarlMember 2020-01-01 2020-03-31 0001578845 agn:AllerganFundingScsMember 2020-01-01 2020-03-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2020-01-01 2020-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2020-01-01 2020-03-31 0001578845 srt:ConsolidationEliminationsMember 2020-01-01 2020-03-31 0001578845 agn:NonGuarantorsMember 2019-01-01 2019-03-31 0001578845 agn:AllerganCapitalSarlMember 2019-01-01 2019-03-31 0001578845 agn:AllerganFundingScsMember 2019-01-01 2019-03-31 0001578845 agn:AllerganFinanceLimitedLiabilityCompanyMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-01-01 2019-03-31 0001578845 srt:ConsolidationEliminationsMember 2019-01-01 2019-03-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2018-12-31 0001578845 agn:AllerganCapitalSarlMember 2018-12-31 0001578845 agn:AllerganFundingScsMember 2018-12-31 0001578845 agn:NonGuarantorsMember 2018-12-31 0001578845 agn:WarnerChilcottLimitedParentGuarantorMember 2019-03-31 0001578845 agn:AllerganCapitalSarlMember 2019-03-31 0001578845 agn:AllerganFundingScsMember 2019-03-31 0001578845 agn:NonGuarantorsMember 2019-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2019~~2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number	Exact name of registrant as specified in its charter, principal office and address and telephone number	State of incorporation or organization	I.R.S. Employer Identification No.
001-36867	Allergan plc Clonshaugh Business and Technology Park Coolock, Dublin, D17 E400, Ireland (862) 261-7000	Ireland	98-1114402

001-36887	Warner Chilcott Limited	Bermuda	98-0496358
	Victoria Place, 5^th Floor
	Hamilton HM 10
	Bermuda
	(441) 295-2244

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Allergan plc Ordinary Shares, $0.0001 par value	AGN	New York Stock Exchange
Floating rate notes due 2020	AGN20A	New York Stock Exchange
0.500% notes due 2021	AGN21	New York Stock Exchange
1.500% notes due 2023	AGN 23A	New York Stock Exchange
1.250% notes due 2024	AGN 24A	New York Stock Exchange
2.625% notes due 2028	AGN28	New York Stock Exchange
2.125% notes due 2029	AGN29	New York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Allergan plc Ordinary Shares, $0.0001 par value	AGN	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Allergan plc		YES ☒		NO ☐
Warner Chilcott Limited		YES ☒		NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Allergan plc		YES ☒		NO ☐
Warner Chilcott Limited		YES ☒		NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Allergan plc	Large accelerated filer	☒	Accelerated filer	☐
	Non-accelerated filer	☐	Smaller reporting company	☐
	Emerging growth company	☐

Warner Chilcott Limited	Large accelerated filer	☐	Accelerated filer	☐
	Non-accelerated filer	☒	Smaller reporting company	☐
	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Allergan plc		YES ☐		NO ☒
Warner Chilcott Limited		YES ☐		NO ☒

Number of shares of Allergan plc’s Ordinary Shares outstanding on ~~November~~May 1, ~~2019~~2020: ~~328~~329,~~277~~805,~~336~~791. There is no trading market for securities of Warner Chilcott Limited, all of which are indirectly wholly owned by Allergan plc.

This Quarterly Report on Form 10-Q is a combined report being filed separately by two different registrants: Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc. The information in this Quarterly Report on Form 10-Q is equally applicable to Allergan plc and Warner Chilcott Limited, except where otherwise indicated. Warner Chilcott Limited meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q and, to the extent applicable, is therefore filing this form with a reduced disclosure format.

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER~~MARCH 3031, ~~2019~~2020

		PAGE
PART I. FINANCIAL INFORMATION
Item 1.	Consolidated Financial Statements (unaudited)	3
	Consolidated Balance Sheets of Allergan plc as of September 30, 2019 and December 31, 2018	3
	Consolidated Balance Sheets of Allergan plc as of March 31, 2020 and December 31, 2019	3
	Consolidated Statements of Operations of Allergan plc for the three and nine months ended September 30, 2019 and September 30, 2018	4
	Consolidated Statements of Operations of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	4
	Consolidated Statements of Comprehensive Income / (Loss) of Allergan plc for the three and nine months ended September 30, 2019 and September 30, 2018	5
	Consolidated Statements of Comprehensive Income / (Loss) of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	5
	Consolidated Statements of Cash Flows of Allergan plc for the nine months ended September 30, 2019 and September 30, 2018	6
	Consolidated Statements of Cash Flows of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	6
	Consolidated Statements of Equity of Allergan plc for the three and nine months ended September 30, 2019 and September 30, 2018	7
	Consolidated Statements of Equity of Allergan plc for the three months ended March 31, 2020 and March 31, 2019	7
	Consolidated Balance Sheets of Warner Chilcott Limited as of September 30, 2019 and December 31, 2018	8
	Consolidated Balance Sheets of Warner Chilcott Limited as of March 31, 2020 and December 31, 2019	8
	Consolidated Statements of Operations of Warner Chilcott Limited for the three and nine months ended September 30, 2019 and September 30, 2018	9
	Consolidated Statements of Operations of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	9
	Consolidated Statements of Comprehensive Income / (Loss) of Warner Chilcott Limited for the three and nine months ended September 30, 2019 and September 30, 2018	10
	Consolidated Statements of Comprehensive Income / (Loss) of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	10
	Consolidated Statements of Cash Flows of Warner Chilcott Limited for the nine months ended September 30, 2019 and September 30, 2018	11
	Consolidated Statements of Cash Flows of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	11
	Consolidated Statements of Equity of Warner Chilcott Limited for the three and nine months ended September 30, 2019 and September 30, 2018	12
	Consolidated Statements of Equity of Warner Chilcott Limited for the three months ended March 31, 2020 and March 31, 2019	12
	Notes to the Consolidated Financial Statements	13
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	6454
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	8770
Item 4.	Controls and Procedures	8871
PART II. OTHER INFORMATION		9073
Item 1.	Legal Proceedings	9073
Item 1A.	Risk Factors	9073
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	9374
Item 6.	Exhibits	9475
	Signatures	9576

PART I. FINANCIAL INFORMATION

ITEM 1.

CONSOLIDATED FINANCIAL STATEMENTS

ALLERGAN PLC

CONSOLIDATED BALANCE SHEETS

(Unaudited; in millions, except par value)

	September 30,		December 31,
	March 31,		December 31,
	2019		2018
	2020		2019
ASSETS
Current assets:
Cash and cash equivalents	$	~~1,237~~999.5	$	~~880~~2,503.43
Marketable securities		31,~~318~~618.48		13,~~026~~411.96
Accounts receivable, net		3,012.3		2,868.1
Accounts receivable, net of allowances for doubtful accounts and credit losses of $144.8 and $110.8		2,800.6		3,192.3
Inventories		1,~~083~~199.19		~~846~~1,133.91
Current assets held for sale		-		34.0
Prepaid expenses and other current assets		855.3		886.4
Prepaid expenses and other current assets		942.3		819.1
Total current assets		7,474.1		11,126.7
Total current assets		9,593.6		6,475.4
Property, plant and equipment, net		1,915.4		1,926.5
Property, plant and equipment, net		1,857.0		1,787.0
Right of use asset - operating leases		481.0		490.4
Right of use asset - operating leases		478.2		-
Investments and other assets		430.7		408.0
Investments and other assets		367.9		1,970.6
Non current assets held for sale		31.7		31.7
Non current assets held for sale		32.5		882.2
Deferred tax assets		597.9		576.9
Deferred tax assets		487.4		1,063.7
Product rights and other intangibles		36,266.2		37,890.6
Product rights and other intangibles		39,526.8		43,695.4
Goodwill		41,229.2		42,248.3
Goodwill		42,065.5		45,913.3
Total assets	$	88,426.2	$	94,699.1
Total assets	$	94,408.9	$	101,787.6
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	5,~~692~~289.25	$	46,~~787~~348.27
Income taxes payable		8873.94		7265.41
Current portion of long-term debt		31,~~739~~950.27		~~868~~4,532.35
Current portion of lease liability - operating		~~118~~119.48		-124.4
Total current liabilities		97,~~638~~433.74		511,~~727~~070.97
Long-term debt		1817,~~786~~599.0		2218,~~929~~116.45
Lease liability - operating		~~437~~438.43		-446.1
Other long-term liabilities		~~810~~787.94		~~882~~800.09
Other taxes payable		1,~~718~~690.4		1,~~615~~704.58
Deferred tax liabilities		42,~~519~~456.32		54,~~501~~363.87
Total liabilities		3530,~~910~~404.7		36,~~656~~502.67
Commitments and contingencies (Refer to Note 21)
Commitments and contingencies (Refer to Note 15)
Equity:
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 328.1 million and 332.6 million shares issued and outstanding, respectively	$	-	$	-
Ordinary shares; $0.0001 par value per share; 1,000.0 million shares authorized, 329.7 million and 328.6 million shares issued and outstanding, respectively	$	-	$	-
Additional paid-in capital		5556,~~882~~036.42		5655,~~510~~974.09
Retained earnings		~~1,551~~882.75		~~7,258~~991.95
Accumulated other comprehensive income		1,~~041~~079.10		1,~~345~~207.2
Total shareholders’ equity		5857,~~475~~997.27		6558,~~114~~173.16
Noncontrolling interest		23.08		1622.98
Total equity		58,~~498~~021.25		6558,~~131~~196.04
Total liabilities and equity	$	9488,~~408~~426.92	$	~~101~~94,~~787~~699.61

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in millions, except per share amounts)

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Net revenues	$	43,~~050~~604.74		$	3,~~911~~597.41		$	~~11,737.9~~		$	~~11,707.7~~
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		~~639~~623.01			~~596~~497.8			~~1,789.1~~			~~1,601.4~~
Research and development		~~474~~430.50			~~424~~435.20			~~1,359.5~~			~~1,588.1~~
Selling and marketing		~~901~~972.41			~~755~~804.60			~~2,578.7~~			~~2,409.0~~
General and administrative		~~1,092~~401.73			~~289~~308.23			~~1,725.2~~			~~919.2~~
Amortization		1,~~537~~416.74			1,~~588~~399.54			~~4,339.1~~			~~4,983.2~~
Goodwill impairments		-913.0			-2,467.0			~~3,552.8~~			-
In-process research and development impairments		-			-			436.0			798.0
Asset sales and impairments, net		148.1			(5.2	)
Asset sales and impairments, net		2.0			(0.4	)		126.2			272.3
Total operating expenses		4,904.0			5,906.3
Total operating expenses		4,647.3			3,653.9			15,906.6			12,571.2
Operating (loss) / income		(1,299.6	)		(2,309.2	)
Operating (loss) / income		(596.6	)		257.5			(4,168.7	)		(863.5	)
Interest income		21.2			21.3
Interest income		20.5			10.0			51.5			33.6
Interest (expense)		(184.5	)		(201.8	)
Interest (expense)		(193.9	)		(220.4	)		(591.1	)		(701.0	)
Other income / (expense), net		(24.9	)		13.8
Other income, net		2.5			130.0			11.6			266.6
Total other (expense), net		(188.2	)		(166.7	)
Total other (expense), net		(170.9	)		(80.4	)		(528.0	)		(400.8	)
(Loss) before income taxes and noncontrolling interest		(1,487.8	)		(2,475.9	)
(Loss) / income before income taxes and noncontrolling interest		(767.5	)		177.1			(4,696.7	)		(1,264.3	)
(Benefit) for income taxes		(1,866.8	)		(68.6	)
Provision (benefit) for income taxes		18.1			213.4			251.1			(474.0	)
Net income / (loss)		379.0			(2,407.3	)
Net (loss)		(785.6	)		(36.3	)		(4,947.8	)		(790.3	)
(Income) attributable to noncontrolling interest		(1.0	)		(0.7	)
(Income) attributable to noncontrolling interest		(1.2	)		(1.6	)		(6.0	)		(6.2	)
Net Income / (loss) attributable to shareholders	$	378.0		$	(2,408.0	)
Net (loss) attributable to shareholders		(786.8	)		(37.9	)		(4,953.8	)		(796.5	)
Income / (Loss) per share attributable to shareholders
Dividends on preferred shares		-			-			-			46.4
Basic	$	1.15		$	(7.25	)
Net (loss) attributable to ordinary shareholders	$	(786.8	)	$	(37.9	)	$	(4,953.8	)	$	(842.9	)
Diluted	$	1.14		$	(7.25	)
(Loss) per share attributable to ordinary shareholders
Weighted average shares outstanding:
Basic	$	(2329.401	)	$	(0332.110	)	$	~~(15.04~~	)	$	~~(2.50~~	)
Diluted	$	(2331.409	)	$	(0332.110	)	$	~~(15.04~~	)	$	~~(2.50~~	)
Weighted average shares outstanding:
Basic		328.0			339.0			329.3			337.6
Diluted		328.0			339.0			329.3			337.6

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME / (LOSS)

(Unaudited; in millions)

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Net (loss)	$	(785.6	)	$	(36.3	)	$	(4,947.8	)	$	(790.3	)
Net income / (loss)	$	379.0		$	(2,407.3	)
Other comprehensive (loss) / income
Foreign currency translation (losses)		(~~241~~127.32	)		(87127.38	)		~~(302.6~~	)		~~(352.1~~	)
Unrealized gains / (losses), net of tax		0.7			(1.4	)		(1.5	)		(1.4	)
Unrealized (losses), net of tax		(1.0	)		(1.0	)
Total other comprehensive (loss), net of tax		(~~240~~128.62	)		(88128.78	)		~~(304.1~~	)		~~(353.5~~	)
Comprehensive (loss)		(1,026.2	)		(125.0	)		(5,251.9	)		(1,143.8	)
Comprehensive income / (loss)		250.8			(2,536.1	)
Comprehensive (income) attributable to noncontrolling interest		(1.20	)		(10.67	)		~~(6.0~~	)		~~(6.2~~	)
Comprehensive (loss) attributable to ordinary shareholders	$	(1,027.4	)	$	(126.6	)	$	(5,257.9	)	$	(1,150.0	)
Comprehensive income / (loss) attributable to ordinary shareholders	$	249.8		$	(2,536.8	)

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in millions)

	Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018
	2020			2019
Cash Flows From Operating Activities:
Net (loss)	$	(4,947.8	)	$	(790.3	)
Net income / (loss)	$	379.0		$	(2,407.3	)
Reconciliation to net cash provided by operating activities:
Depreciation		~~150~~56.68			~~149~~47.75
Amortization		41,~~339~~416.14			41,~~983~~399.24
Provision for inventory reserve		~~127~~28.84			7418.98
Share-based compensation		~~161~~51.76			~~185~~52.23
Deferred income tax benefit		(~~365~~1,931.31	)		(~~1,362~~229.87	)
Goodwill impairments		~~3,552~~913.80			-2,467.0
In-process research and development impairments		436.0			798.0
(Gain) / loss on asset sales and impairments, net		148.1			(5.2	)
Loss on asset sales and impairments, net		126.2			272.3
Non-cash extinguishment of debt		-			0.3
Gain on sale of Teva securities, net		-			(60.9	)
Amortization of deferred financing costs		4.1			4.6
Gain on sale of businesses		-			(182.6	)
Non-cash lease expense		35.9			30.1
Non-cash extinguishment of debt		0.2			17.4
Contingent consideration adjustments, including accretion		26.6			18.7
Cash charge related to extinguishment of debt		-			(18.2	)
Other, net		65.2			(10.3	)
Amortization of deferred financing costs		13.3			17.4
Non-cash lease expense		93.5			-
Contingent consideration adjustments, including accretion		49.5			(113.1	)
Other, net		(2.3	)		0.5
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net		~~(184~~330.62	)		17132.04
Decrease / (increase) in inventories		(~~328~~126.93	)		(~~136~~128.23	)
Decrease / (increase) in prepaid expenses and other current assets		(3620.21	)		(536.42	)
Increase / (decrease) in accounts payable and accrued expenses		~~874~~(1,242.9	)		(46199.18	)
Increase / (decrease) in income and other net taxes payable		~~1,638~~2.71			~~415~~60.50
Increase / (decrease) in other assets and liabilities		(~~130~~20.85	)		(7452.07	)
Net cash provided by operating activities		~~5,568~~116.45			41,~~141~~234.50
Cash Flows From Investing Activities:
Additions to property, plant and equipment		(~~253~~60.34	)		(~~165~~64.18	)
Additions to product rights and other intangibles		(4657.06	)		-(7.5	)
Additions to investments		(~~3,738~~5.0	)		(~~1,456~~538.42	)
Proceeds from sale of investments and other assets		1,~~466~~800.70			~~6,201~~569.31
Payments to settle Teva related matters		-			(466.0	)
Proceeds from sales of property, plant and equipment		2.1			17.2
Proceeds from sales of property, plant and equipment		18.5			24.6
Acquisitions of businesses, net of cash acquired		-			(80.6	)
Acquisitions of businesses, net of cash acquired		(80.6	)		-
Net cash (used in) / provided by investing activities		1,679.1			(104.8	)
Net cash (used in) / provided by investing activities		(2,632.7	)		4,138.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility		3.3			717.2
Payments on debt, including finance lease obligations and credit facility		(3,031.8	)		(159.4	)
Payments on debt, including finance lease obligations and credit facility		(1,044.9	)		(7,115.9	)
Payments of contingent consideration and other financing		(2.8	)		(2.0	)
Payments of contingent consideration and other financing		(6.3	)		(21.7	)
Proceeds from stock plans		64.4			9.7
Proceeds from stock plans		45.0			98.2
Repurchase of ordinary shares		(54.7	)		(829.2	)
Proceeds from forward sale of Teva securities		-			465.5
Dividends paid		(243.5	)		(246.1	)
Payments to settle Teva related matters		-			(234.0	)
Net cash (used in) financing activities		(3,268.4	)		(1,227.0	)
Repurchase of ordinary shares		(834.3	)		(2,023.5	)
Effect of currency exchange rate changes on cash and cash equivalents		(31.0	)		5.9
Dividends paid		(731.4	)		(808.1	)
Net increase / (decrease) in cash and cash equivalents		(1,503.8	)		(91.9	)
Net cash (used in) financing activities		(2,568.6	)		(8,922.3	)
Cash and cash equivalents at beginning of period		2,503.3			880.4
Effect of currency exchange rate changes on cash and cash equivalents		(10.0	)		13.1
Cash and cash equivalents at end of period	$	999.5		$	788.5
Net increase / (decrease) in cash and cash equivalents		357.1			(629.3	)
Cash and cash equivalents at beginning of period		880.4			1,817.2
Cash and cash equivalents at end of period	$	1,237.5		$	1,187.9
Supplemental Disclosures of Cash Flow Information
Cash paid during the year for:
Income taxes other, net of refunds	$	~~(1,019~~68.87	)	$	~~510~~105.14
Interest	$	~~642~~237.26		$	~~817~~252.60
Schedule of Non-Cash Investing and Financing Activities:
Conversion of mandatory convertible preferred shares	$	-		$	4,929.7
Dividends accrued	$	244.5		$	1.4
Settlement of Teva Shares	$	-		$	465.5
Settlement of secured financing	$	-		$	(465.5	)
Dividends accrued	$	1.1		$	1.4

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited; in millions)

															Retained			Accumulated
												Accumulated
						Additional						~~Additional~~Other			~~Earnings/~~			~~Other~~
	Ordinary Shares					~~Preferred Shares~~Paid-in-			Retained			~~Paid-in-~~Comprehensive			~~(Accumulated~~Noncontrolling			~~Comprehensive~~			~~Noncontrolling~~
	Shares			Amount		~~Shares~~Capital			~~Amount~~Earnings			~~Capital~~Income / (Loss)			~~Deficit)~~Interest			~~Income / (Loss)~~Total			~~Interest~~			~~Total~~
BALANCE, December 31, 2017		330.2		$	-		5.1		$	4,929.7		$	54,013.5		$	12,957.2		$	1,920.7		$	16.0		$	73,837.1
BALANCE, December 31, 2018		332.6		$	-	$	56,510.0		$	7,258.9		$	1,345.2		$	16.9		$	65,131.0
Implementation of new accounting pronouncements		-			-		-			-			-			424.7			(63.0	)		-			361.7
Implementation of new accounting pronouncement		-			-		-			(22.0	)		-			-			(22.0	)
BALANCE, January 1, 2018		330.2		$	-		5.1		$	4,929.7		$	54,013.5		$	13,381.9		$	1,857.7		$	16.0		$	74,198.8
BALANCE, January 1, 2019		332.6		$	-	$	56,510.0		$	7,236.9		$	1,345.2		$	16.9		$	65,109.0
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-(2,408.0	)		-			~~(286.1~~-	)		-(2,408.0	)		-			~~(286.1~~	)
Other comprehensive income, net of tax		-			-		-			-			-			-			183.8			-			183.8
Other comprehensive (loss), net of tax		-			-		-			-			(128.8	)		-			(128.8	)
Share-based compensation		-			-		-52.3			-			~~72.5~~-			-			-52.3			-			~~72.5~~
Ordinary shares issued under employee stock plans		0.7			-		-9.7			-			~~35.5~~-			-			-9.7			-			~~35.5~~
Dividends declared		-			-		-			-(246.1	)		-			~~(296.3~~-	)		-(246.1	)		-			~~(296.3~~	)
Conversion of Mandatory Preferred Shares		17.8			-		(5.1	)		(4,929.7	)		4,929.7			-			-			-			-
Repurchase of ordinary shares under the share repurchase programs		(5.3	)		-		(799.7	)		-			-			-			(799.7	)
Repurchase of ordinary shares under the share repurchase programs		(9.6	)		-		-			-			(1,540.0	)		-			-			-			(1,540.0	)
Repurchase of ordinary shares		(0.2	)		-		(29.5	)		-			-			-			(29.5	)
Repurchase of ordinary shares		(0.1	)		-		-			-			(24.3	)		-			-			-			(24.3	)
Movement in noncontrolling interest		-			-		-			-			-			0.7			0.7
Movement in noncontrolling interest		-			-		-			-			-			-			-			2.1			2.1
BALANCE, March 31, 2019		327.8		$	-	$	55,742.8		$	4,582.8		$	1,216.4		$	17.6		$	61,559.6
BALANCE, March 31, 2018		339.0		$	-		-		$	-		$	57,486.9		$	12,799.5		$	2,041.5		$	18.1		$	72,346.0
BALANCE, December 31, 2019		328.6		$	-	$	55,974.9		$	991.5		$	1,207.2		$	22.8		$	58,196.4
Comprehensive (loss):
Comprehensive income:
Net (loss) attributable to shareholders		-			-		-			-			-			(472.5	)		-			-			(472.5	)
Net income attributable to shareholders		-			-		-			378.0			-			-			378.0
Other comprehensive (loss), net of tax		-			-		-			-			-			-			(448.6	)		-			(448.6	)
Other comprehensive income, net of tax		-			-		-			-			(128.2	)		-			(128.2	)
Share-based compensation		-			-		-51.6			-			~~54.9~~-			-			-51.6			-			~~54.9~~
Ordinary shares issued under employee stock plans		01.34			-		-64.4			-			~~33.7~~-			-			-64.4			-			~~33.7~~
Dividends declared		-			-		-			-(487.0	)		-			~~(244.1~~-	)		-(487.0	)		-			~~(244.1~~	)
Repurchase of ordinary shares		-(0.3	)		-		-(54.7	)		-			~~(7.8~~-	)		-			-(54.7	)		-			~~(7.8~~	)
Movement in noncontrolling interest		-			-		-			-			-			-1.0			-1.0			~~2.4~~			~~2.4~~
BALANCE, June 30, 2018		339.3		$	-		-		$	-		$	57,567.7		$	12,082.9		$	1,592.9		$	20.5		$	71,264.0
BALANCE, March 31, 2020		329.7			-		56,036.2			882.5			1,079.0			23.8			58,021.5
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-			-			(37.9	)		-			-			(37.9	)
Other comprehensive (loss), net of tax		-			-		-			-			-			-			(88.7	)		-			(88.7	)
Share-based compensation		-			-		-			-			57.8			-			-			-			57.8
Ordinary shares issued under employee stock plans		0.3			-		-			-			29.0			-			-			-			29.0
Dividends declared		-			-		-			-			-			(244.4	)		-			-			(244.4	)
Repurchase of ordinary shares under the share repurchase programs		(2.4	)		-		-			-			(450.1	)		-			-			-			(450.1	)
Repurchase of ordinary shares		-			-		-			-			(1.4	)		-			-			-			(1.4	)
Movement in noncontrolling interest		-			-		-			-			-			-			-			(7.4	)		(7.4	)
BALANCE, September 30, 2018		337.2		$	-		-		$	-		$	57,203.0		$	11,800.6		$	1,504.2		$	13.1		$	70,520.9
BALANCE, December 31, 2018		332.6		$	-		-		$	-		$	56,510.0		$	7,258.9		$	1,345.2		$	16.9		$	65,131.0
Implementation of new accounting pronouncement		-			-		-			-			-			(22.0	)		-			-			(22.0	)
BALANCE, January 1, 2019		332.6		$	-		-		$	-		$	56,510.0		$	7,236.9		$	1,345.2		$	16.9		$	65,109.0
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-			-			(2,408.0	)		-			-			(2,408.0	)
Other comprehensive (loss), net of tax		-			-		-			-			-			-			(128.8	)		-			(128.8	)
Share-based compensation		-			-		-			-			52.3			-			-			-			52.3
Ordinary shares issued under employee stock plans		0.7			-		-			-			9.7			-			-			-			9.7
Dividends declared		-			-		-			-			-			(246.1	)		-			-			(246.1	)
Repurchase of ordinary shares under the share repurchase programs		(5.3	)		-		-			-			(799.7	)		-			-			-			(799.7	)
Repurchase of ordinary shares		(0.2	)		-		-			-			(29.5	)		-			-			-			(29.5	)
Movement in noncontrolling interest		-			-		-			-			-			-			-			0.7			0.7
BALANCE, March 31, 2019		327.8		$	-		-		$	-		$	55,742.8		$	4,582.8		$	1,216.4		$	17.6		$	61,559.6
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-			-			(1,759.0	)		-			-			(1,759.0	)
Other comprehensive income, net of tax		-			-		-			-			-			-			65.3			-			65.3
Share-based compensation		-			-		-			-			59.5			-			-			-			59.5
Ordinary shares issued under employee stock plans		0.1			-		-			-			13.9			-			-			-			13.9
Dividends declared		-			-		-			-			-			(242.7	)		-			-			(242.7	)
Repurchase of ordinary shares		-			-		-			-			(4.3	)		-			-			-			(4.3	)
Movement in noncontrolling interest		-			-		-			-			-			-			-			3.8			3.8
BALANCE, June 30, 2019		327.9		$	-		-		$	-		$	55,811.9		$	2,581.1		$	1,281.7		$	21.4		$	59,696.1
Comprehensive (loss):
Net (loss) attributable to shareholders		-			-		-			-			-			(786.8	)		-			-			(786.8	)
Other comprehensive (loss), net of tax		-			-		-			-			-			-			(240.6	)		-			(240.6	)
Share-based compensation		-			-		-			-			49.9			-			-			-			49.9
Ordinary shares issued under employee stock plans		0.2			-		-			-			21.4			-			-			-			21.4
Dividends declared		-			-		-			-			-			(242.6	)		-			-			(242.6	)
Repurchase of ordinary shares		-			-		-			-			(0.8	)		-			-			-			(0.8	)
Movement in noncontrolling interest		-			-		-			-			-			-			-			1.6			1.6
BALANCE, September 30, 2019		328.1		$	-		-		$	-		$	55,882.4		$	1,551.7		$	1,041.1		$	23.0		$	58,498.2

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED BALANCE SHEETS

(Unaudited; in millions)

	September 30,			December 31,
	March 31,			December 31,
	2019			2018
	2020			2019
ASSETS
Current assets:
Cash and cash equivalents	$	~~1,230~~990.35		$	~~878~~2,497.61
Marketable securities		31,~~318~~618.48			13,~~026~~411.96
Accounts receivable, net		3,012.3			2,868.1
Accounts receivable, net of allowances for doubtful accounts and credit losses of $144.8 and $110.8		2,800.6			3,192.3
Receivables from Parents		~~286~~539.50			~~640~~409.93
Inventories		1,~~083~~199.19			~~846~~1,133.91
Current assets held for sale		-			34.0
Prepaid expenses and other current assets		855.3			886.4
Prepaid expenses and other current assets		940.7			818.7
Total current assets		8,004.1			11,529.8
Total current assets		9,871.3			7,114.1
Property, plant and equipment, net		1,915.4			1,926.5
Property, plant and equipment, net		1,857.0			1,787.0
Right of use asset - operating leases		481.0			490.4
Right of use asset - operating leases		478.2			-
Investments and other assets		430.7			408.0
Investments and other assets		367.9			1,970.6
Non current assets held for sale		31.7			31.7
Non current assets held for sale		32.5			882.2
Deferred tax assets		597.9			576.9
Deferred tax assets		487.4			1,063.7
Product rights and other intangibles		36,266.2			37,890.6
Product rights and other intangibles		39,526.8			43,695.4
Goodwill		41,229.2			42,248.3
Goodwill		42,065.5			45,913.3
Total assets	$	88,956.2		$	95,102.2
Total assets	$	94,686.6		$	102,426.3
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	5,~~690~~044.69		$	46,~~787~~347.40
Payables to Parents		2,~~581~~899.69			2,~~829~~715.25
Income taxes payable		8873.95			7265.41
Current portion of long-term debt		31,~~739~~950.27			~~868~~4,532.35
Current portion of lease liability - operating		~~118~~119.48			-124.4
Total current liabilities		1210,~~218~~088.78			813,~~557~~784.35
Long-term debt		1817,~~786~~599.0			2218,~~929~~116.45
Lease liability - operating		~~437~~438.43			-446.1
Other long-term liabilities		~~810~~787.9			~~882~~801.04
Other taxes payable		1,~~713~~683.49			1,~~615~~698.56
Deferred tax liabilities		42,~~519~~455.38			54,~~501~~363.82
Total liabilities		3833,~~485~~053.7			39,~~486~~210.03
Commitments and contingencies (Refer to Note 21)
Commitments and contingencies (Refer to Note 15)
Equity:
Members' capital		6463,~~266~~780.71			6564,~~797~~023.96
Retained earnings		(9,129.9	)		(4,219.7	)
(Accumulated deficit)		(8,980.4	)		(9,361.7	)
Accumulated other comprehensive income		1,~~041~~079.10			1,~~345~~207.2
Total members’ equity		5655,~~177~~878.97			6255,~~923~~869.41
Noncontrolling interest		23.08			1622.98
Total equity		5655,~~200~~902.95			6255,~~940~~891.39
Total liabilities and equity	$	9488,~~686~~956.62		$	~~102~~95,~~426~~102.32

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in millions)

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Net revenues	$	43,~~050~~604.74		$	3,~~911~~597.41		$	~~11,737.9~~		$	~~11,707.7~~
Operating expenses:
Cost of sales (excludes amortization and impairment of acquired intangibles including product rights)		~~639~~623.01			~~596~~497.8			~~1,789.1~~			~~1,601.4~~
Research and development		~~474~~430.50			~~424~~435.20			~~1,359.5~~			~~1,588.1~~
Selling and marketing		~~901~~972.41			~~755~~804.60			~~2,578.7~~			~~2,409.0~~
General and administrative		~~1,037~~398.10			~~272~~306.41			~~1,659.6~~			~~866.0~~
Amortization		1,~~537~~416.74			1,~~588~~399.54			~~4,339.1~~			~~4,983.2~~
Goodwill impairments		-913.0			-2,467.0			~~3,552.8~~			-
In-process research and development impairments		-			-			436.0			798.0
Asset sales and impairments, net		148.1			(5.2	)
Asset sales and impairments, net		2.0			(0.4	)		126.2			272.3
Total operating expenses		4,900.7			5,904.1
Total operating expenses		4,591.7			3,637.1			15,841.0			12,518.0
Operating (loss) / income		(1,296.3	)		(2,307.0	)
Operating (loss) / income		(541.0	)		274.3			(4,103.1	)		(810.3	)
Interest income		21.2			21.3
Interest income		20.5			77.3			51.5			219.4
Interest (expense)		(184.5	)		(201.8	)
Interest (expense)		(193.9	)		(220.4	)		(591.1	)		(701.0	)
Other (expense) income, net		(24.9	)		13.8
Other income, net		2.5			130.0			11.6			266.6
Total other (expense), net		(188.2	)		(166.7	)
Total other (expense), net		(170.9	)		(13.1	)		(528.0	)		(215.0	)
(Loss) / income before income taxes and noncontrolling interest		(1,484.5	)		(2,473.7	)
(Loss) / income before income taxes and noncontrolling interest		(711.9	)		261.2			(4,631.1	)		(1,025.3	)
(Benefit) for income taxes		(1,866.8	)		(68.7	)
Provision / (benefit) for income taxes		18.2			208.3			251.1			(479.1	)
Net income / (loss)		382.3			(2,405.0	)
Net (loss) / income		(730.1	)		52.9			(4,882.2	)		(546.2	)
(Income) attributable to noncontrolling interest		(1.0	)		(0.7	)
(Income) attributable to noncontrolling interest		(1.2	)		(1.6	)		(6.0	)		(6.2	)
Net income / (loss) attributable to members	$	381.3		$	(2,405.7	)
Net (loss) / income attributable to members	$	(731.3	)	$	51.3		$	(4,888.2	)	$	(552.4	)

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME / (LOSS)

(Unaudited; in millions)

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Net (loss) / income	$	(730.1	)	$	52.9		$	(4,882.2	)	$	(546.2	)
Net income / (loss)	$	382.3		$	(2,405.0	)
Other comprehensive (loss) / income
Foreign currency translation (losses)		(~~241~~127.32	)		(87127.38	)		~~(302.6~~	)		~~(352.1~~	)
Unrealized gains / (losses), net of tax		0(1.70	)		(1.40	)		~~(1.5~~	)		~~(1.4~~	)
Total other comprehensive (loss), net of tax		(~~240~~128.62	)		(88128.78	)		~~(304.1~~	)		~~(353.5~~	)
Comprehensive (loss)		(970.7	)		(35.8	)		(5,186.3	)		(899.7	)
Comprehensive income / (loss)		254.1			(2,533.8	)
Comprehensive (income) attributable to noncontrolling interest		(1.20	)		(10.67	)		~~(6.0~~	)		~~(6.2~~	)
Comprehensive (loss) attributable to members	$	(971.9	)	$	(37.4	)	$	(5,192.3	)	$	(905.9	)
Comprehensive income / (loss) attributable to members	$	253.1		$	(2,534.5	)

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in millions)

	Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018
	2020			2019
Cash Flows From Operating Activities:
Net (loss)	$	(4,882.2	)	$	(546.2	)
Net income / (loss)	$	382.3		$	(2,405.0	)
Reconciliation to net cash provided by operating activities:
Depreciation		~~150~~56.68			~~149~~47.75
Amortization		41,~~339~~416.14			41,~~983~~399.24
Provision for inventory reserve		~~127~~28.84			7418.98
Share-based compensation		~~161~~51.76			~~185~~52.23
Deferred income tax benefit		(~~365~~1,931.31	)		(~~1,362~~229.87	)
Goodwill impairments		~~3,552~~913.80			-2,467.0
In-process research and development impairments		436.0			798.0
(Gain) / loss on asset sales and impairments, net		148.1			(5.2	)
Loss on asset sales and impairments, net		126.2			272.3
Non-cash extinguishment of debt		-			0.3
Gain on sale of Teva securities, net		-			(60.9	)
Amortization of deferred financing costs		4.1			4.6
Gain on sale of businesses		-			(182.6	)
Non-cash lease expense		35.9			30.1
Non-cash extinguishment of debt		0.2			17.4
Contingent consideration adjustments, including accretion		26.6			18.7
Cash charge related to extinguishment of debt		-			(18.2	)
Other, net		65.2			(10.3	)
Amortization of deferred financing costs		13.3			17.4
Non-cash lease expense		93.5			-
Contingent consideration adjustments, including accretion		49.5			(113.1	)
Other, net		(2.3	)		0.5
Changes in assets and liabilities (net of effects of acquisitions):
Decrease / (increase) in accounts receivable, net		~~(184~~330.62	)		17132.04
Decrease / (increase) in inventories		(~~328~~126.93	)		(~~136~~128.23	)
Decrease / (increase) in prepaid expenses and other current assets		(3520.01	)		(440.54	)
Increase / (decrease) in accounts payable and accrued expenses		~~876~~(1,000.70	)		(43199.75	)
Increase / (decrease) in income and other net taxes payable		~~1,638~~2.71			~~415~~60.50
Increase / (decrease) in other assets and liabilities, including receivable / payable with Parents		(~~194~~259.38	)		(~~257~~79.73	)
Net cash provided by operating activities		~~5,573~~123.54			41,~~205~~214.2
Cash Flows From Investing Activities:
Additions to property, plant and equipment		(~~253~~60.34	)		(~~165~~64.18	)
Additions to product rights and other intangibles		(4657.06	)		-(7.5	)
Additions to investments		(~~3,738~~5.0	)		(~~1,456~~538.42	)
Proceeds from sale of investments and other assets		1,~~466~~800.70			~~6,201~~569.31
Payments to settle Teva related matters		-			(466.0	)
Proceeds from sales of property, plant and equipment		2.1			17.2
Proceeds from sales of property, plant and equipment		18.5			24.6
Acquisitions of businesses, net of cash acquired		-			(80.6	)
Acquisitions of businesses, net of cash acquired		(80.6	)		-
Net cash (used in) / provided by investing activities		1,679.1			(104.8	)
Net cash (used in) / provided by investing activities		(2,632.7	)		4,138.4
Cash Flows From Financing Activities:
Proceeds from borrowings of long-term indebtedness, including credit facility		3.3			717.2
Payments on debt, including finance lease obligations and credit facility		(3,031.8	)		(159.4	)
Payments on debt, including finance lease obligations and credit facility		(1,044.9	)		(7,115.9	)
Payments of contingent consideration and other financing		(2.8	)		(2.0	)
Payments of contingent consideration and other financing		(6.3	)		(21.7	)
Dividends to Parents		(243.5	)		(1,045.8	)
Proceeds from forward sale of Teva securities		-			465.5
Net cash (used in) financing activities		(3,278.1	)		(1,207.2	)
Payments to settle Teva related matters		-			(234.0	)
Effect of currency exchange rate changes on cash and cash equivalents		(31.0	)		5.9
Dividends to Parents		(1,531.2	)		(2,798.2	)
Net increase / (decrease) in cash and cash equivalents		(1,506.6	)		(91.9	)
Net cash (used in) financing activities		(2,579.1	)		(8,987.1	)
Cash and cash equivalents at beginning of period		2,497.1			878.6
Effect of currency exchange rate changes on cash and cash equivalents		(10.0	)		13.1
Cash and cash equivalents at end of period	$	990.5		$	786.7
Net increase / (decrease) in cash and cash equivalents		351.7			(630.4	)
Cash and cash equivalents at beginning of period		878.6			1,816.3
Cash and cash equivalents at end of period	$	1,230.3		$	1,185.9
Schedule of Non-Cash Investing and Financing Activities:
Settlement of Teva Shares	$	-		$	465.5
Settlement of secured financing	$	-		$	(465.5	)

See accompanying Notes to the Consolidated Financial Statements.

WARNER CHILCOTT LIMITED

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited; in millions, except share data)

	Members' Capital
	Shares		Amount			~~Retained~~(Accumulated ~~Earnings~~Deficit)			Accumulated Other Comprehensive Income / (Loss)			Noncontrolling Interest			Total
BALANCE, December 31, 2017		100.0	$	72,935.1		$	6,410.4		$	1,920.7		$	16.0		$	81,282.2
Implementation of new accounting pronouncements		-		-			424.7			(63.0	)		-			361.7
BALANCE, January 1, 2018		100.0	$	72,935.1		$	6,835.1		$	1,857.7		$	16.0		$	81,643.9
Comprehensive (loss):
Net (loss) attributable to members		-		-			(231.3	)		-			-			(231.3	)
Other comprehensive income, net of tax		-		-			-			183.8			-			183.8
Dividends to Parents		-		-			(1,859.5	)		-			-			(1,859.5	)
Movement in noncontrolling interest		-		-			-			-			2.1			2.1
BALANCE, March 31, 2018		100.0	$	72,935.1		$	4,744.3		$	2,041.5		$	18.1		$	79,739.0
Comprehensive (loss):
Net (loss) attributable to members		-		-			(372.4	)		-			-			(372.4	)
Other comprehensive (loss), net of tax		-		-			-			(448.6	)		-			(448.6	)
Dividends to Parents		-		-			(244.2	)		-			-			(244.2	)
Movement in noncontrolling interest		-		-			-			-			2.4			2.4
BALANCE, June 30, 2018		100.0	$	72,935.1		$	4,127.7		$	1,592.9		$	20.5		$	78,676.2
Comprehensive (loss):
Net (loss) attributable to members		-		-			51.3			-			-			51.3
Other comprehensive (loss), net of tax		-		-			-			(88.7	)		-			(88.7	)
Dividends to Parents		-		-			(694.5	)		-			-			(694.5	)
Movement in noncontrolling interest		-		-			-			-			(7.4	)		(7.4	)
BALANCE, September 30, 2018		100.0	$	72,935.1		$	3,484.5		$	1,504.2		$	13.1		$	77,936.9
BALANCE, December 31, 2018		100.0	$	65,797.9		$	(4,219.7	)	$	1,345.2		$	16.9		$	62,940.3
Implementation of new accounting pronouncement		-		-			(22.0	)		-			-			(22.0	)
Implementation of new accounting pronouncements		-		-			(22.0	)		-			-			(22.0	)
BALANCE, January 1, 2019		100.0	$	65,797.9		$	(4,241.7	)	$	1,345.2		$	16.9		$	62,918.3
Comprehensive (loss):
Net (loss) attributable to members		-		-			(2,405.7	)		-			-			(2,405.7	)
Other comprehensive (loss), net of tax		-		-			-			(128.8	)		-			(128.8	)
Dividends to Parents		-		(1,045.8	)		-			-			-			(1,045.8	)
Movement in noncontrolling interest		-		-			-			-			0.7			0.7
BALANCE, March 31, 2019		100.0	$	64,752.1		$	(6,647.4	)	$	1,216.4		$	17.6		$	59,338.7
Comprehensive (loss):
BALANCE, December 31, 2019		100.0	$	64,023.6		$	(9,361.7	)	$	1,207.2		$	22.8		$	55,891.9
Net (loss) attributable to members		-		-			(1,751.2	)		-			-			(1,751.2	)
Comprehensive income:
Other comprehensive income, net of tax		-		-			-			65.3			-			65.3
Net income attributable to members		-		-			381.3			-			-			381.3
Dividends to Parents		-		(242.7	)		-			-			-			(242.7	)
Other comprehensive (loss), net of tax		-		-			-			(128.2	)		-			(128.2	)
Movement in noncontrolling interest		-		-			-			-			3.8			3.8
Dividends to Parents		-		(243.5	)		-			-			-			(243.5	)
BALANCE, June 30, 2019		100.0	$	64,509.4		$	(8,398.6	)	$	1,281.7		$	21.4		$	57,413.9
Movement in noncontrolling interest		-		-			-			-			1.0			1.0
Comprehensive (loss):
BALANCE, March 31, 2020		100.0		63,780.1			(8,980.4	)		1,079.0			23.8			55,902.5
Net (loss) attributable to members		-		-			(731.3	)		-			-			(731.3	)
Other comprehensive (loss), net of tax		-		-			-			(240.6	)		-			(240.6	)
Dividends to Parents		-		(242.7	)		-			-			-			(242.7	)
Movement in noncontrolling interest		-		-			-			-			1.6			1.6
BALANCE, September 30, 2019		100.0	$	64,266.7		$	(9,129.9	)	$	1,041.1		$	23.0		$	56,200.9

See accompanying Notes to the Consolidated Financial Statements.

ALLERGAN PLC AND WARNER CHILCOTT LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 — General

Allergan plc is a global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As a part of its approach to deliver innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry. The Company has operations in more than 100 countries. Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc and has the same principal business activities.

Merger Agreement with AbbVie Inc.

On June 25, 2019, the Company announced that it entered into a transaction agreement (the “AbbVie Agreement”) under which AbbVie Inc. (“AbbVie”), a global, research-driven biopharmaceutical company, would acquire Allergan plc in a stock and cash transaction (the “AbbVie Transaction”), valued at $188.24 per Allergan share, or approximately $63.0 billion, based on AbbVie’s then-current stock price at the time the AbbVie Transaction was announced. At the closing of the proposed AbbVie Transaction, Company shareholders will receive 0.8660 shares of AbbVie common stock and $120.30 in cash for each of their existing shares. On October 14, 2019, the Company’s shareholders voted to approve the AbbVie Transaction. The AbbVie Transaction is subject to customary regulatory approvals and other customary closing conditions. ~~The~~On May 5, 2020 the U.S. Federal Trade Commission (“FTC”) accepted a proposed consent order in connection with the AbbVie Transaction. isUnder ~~anticipated~~the terms of the consent order, the companies have agreed to ~~close~~divest brazikumab, an investigational IL-23 inhibitor in ~~early~~development ~~2020~~for autoimmune diseases, to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, to Nestle Health Science. Nestle also will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.

On ~~October~~May 256, ~~2019~~2020, ~~in connection with~~ the ~~AbbVie~~Irish ~~Transaction,~~High ~~AbbVie~~Court ~~commenced~~(the an“Court”) ~~offer~~approved to exchange all Allergan Senior Notes issued by Allergan and maturing from September 15, 2020 through March 15, 2045 for up to approximately $19.6 billion aggregate principal amount of new notes to be issued by AbbVie and cash. In conjunction with the ~~exchange offer,~~ AbbVie isTransaction ~~concurrently~~at ~~soliciting~~a ~~consents~~sanction ~~from~~hearing ~~eligible~~in ~~holders~~relation ~~of the Allergan Senior Notes~~ to ~~amend each of~~ the ~~indentures~~scheme ~~governing the Allergan Senior Notes to eliminate substantially all~~ of ~~the~~arrangement ~~restrictive covenants in such indentures and eliminate any guarantees of~~ (the ~~related~~“Scheme”) ~~Allergan Senior Notes. The exchange offer~~ (and ~~consent~~to ~~solicitations~~confirm ~~are conditioned upon, among other things,~~ the ~~closing~~associated ofcapital ~~the~~reduction) ~~AbbVie~~under ~~Transaction. The exchange offers are expected to close on or about~~ the ~~closing date of the~~ AbbVie Transaction.

~~The~~Completion ~~accompanying~~of ~~consolidated financial statements should be read in conjunction with~~ the ~~Company’s~~AbbVie ~~annual~~Transaction ~~report~~remains onsubject ~~Form 10-K~~to ~~for~~ the ~~year~~delivery ~~ended December 31~~to, ~~2018 (“Annual Report”). Certain information~~ and ~~footnote~~registration ~~disclosures~~by, ~~normally~~the ~~included~~Registrar inof ~~annual~~Companies ~~financial statements prepared~~ in ~~accordance~~Ireland ~~with~~of ~~United~~copies ~~States~~of ~~generally accepted accounting principles~~ (~~“GAAP”~~i) ~~have been condensed or omitted from~~ the ~~accompanying~~order ~~consolidated~~of ~~financial statements. The accompanying year end consolidated balance sheet was derived from~~ the ~~audited~~Court ~~financial~~sanctioning ~~statements included in~~ the ~~Annual~~Scheme ~~Report. The accompanying interim financial statements are unaudited~~ and ~~reflect~~confirming ~~all adjustments which are in~~ the ~~opinion~~associated ofreduction ~~management necessary for a fair statement~~ of ~~the~~capital; ~~Company’s~~and ~~consolidated financial position, results of operations, comprehensive~~ (~~loss~~ii) ~~/ income and cash flows for~~ the ~~periods~~minute ~~presented.~~required ~~All~~by ~~such~~Section ~~adjustments~~86 ~~are~~ of athe ~~normal,~~Act ~~recurring nature. All intercompany transactions and balances have been eliminated~~ in ~~consolidation.~~respect ~~The Company’s results~~ of ~~operations, comprehensive (loss) / income and cash flows for~~ the ~~interim~~reduction ~~periods are not necessarily indicative~~ of ~~the~~capital, ~~results~~each of ~~operations,~~which ~~comprehensive~~is ~~(loss)~~expected /to ~~income~~occur ~~and~~on ~~cash~~May ~~flows~~8, ~~that it may achieve in future periods~~2020.

Additionally, on October 25, 2019, in connection with the AbbVie Transaction, AbbVie commenced offers to exchange all Allergan Senior Notes issued by Allergan and maturing from September 15, 2020 through March 15, 2045 for up to approximately $19.6 billion aggregate principal amount of new notes to be issued by AbbVie and cash. In conjunction with the exchange offer, AbbVie solicited and obtained consents from eligible holders of the Allergan Senior Notes to amend each of the indentures governing the Allergan Senior Notes to eliminate substantially all of the restrictive covenants in such indentures and eliminate any guarantees of the related Allergan Senior Notes. Consummation of the exchange offer is conditioned upon, among other things, the closing of the AbbVie Transaction. The exchange offers are expected to close, and such amendments are expected to become operative, on or about the closing date of the AbbVie Transaction.

The accompanying consolidated financial statements should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2019 (“Annual Report”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted from the accompanying consolidated financial statements. The accompanying year end consolidated balance sheet was derived from the audited financial statements included in the Annual Report. The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive (loss) / income and cash flows for the periods presented. All such adjustments are of a normal, recurring nature. All intercompany transactions and balances have been eliminated in consolidation. The Company’s results of operations, comprehensive (loss) / income and cash flows for the interim periods are not necessarily indicative of the results of operations, comprehensive (loss) / income and cash flows that it may achieve in future periods.

References throughout to “we,” “our,” “us,” the “Company” or “Allergan” refer to financial information and transactions of Allergan plc. References to “Warner Chilcott Limited” refer to Warner Chilcott Limited, the Company’s indirect wholly-owned subsidiary, and, unless the context otherwise requires, its subsidiaries.

NOTE 2 — Reconciliation of Warner Chilcott Limited results to Allergan plc results

Warner Chilcott Limited is an indirect wholly-owned subsidiary of Allergan plc, the ultimate parent of the group (together with other direct or indirect parents of Warner Chilcott Limited, the “Parents”). The results of Warner Chilcott Limited are consolidated into the results of Allergan plc. Due to the de minimis activity between Warner Chilcott Limited and the Parents (including Allergan plc), content throughout this filing relates to both Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited disclosures relate only to itself and not to any other company. Except where otherwise indicated, and excluding certain insignificant cash and non-cash transactions at the Allergan plc level, these notes relate to the consolidated financial statements for both separate registrants, Allergan plc and Warner Chilcott Limited. In addition to certain inter-company payable and receivable amounts between the entities, the following is a reconciliation of the financial position and results of operations of Warner Chilcott Limited to Allergan plc ($ in millions):

	As of March 31, 2020						As of December 31, 2019
	Allergan plc		Warner Chilcott Limited		Difference		Allergan plc		Warner Chilcott Limited		Difference
Cash and cash equivalents	$	999.5	$	990.5	$	9.0	$	2,503.3	$	2,497.1	$	6.2
Prepaid expenses and other current assets		855.3		855.3		-		886.4		886.4		-
Accounts payable and accrued liabilities		5,289.5		5,044.9		244.6		6,348.7		6,347.0		1.7
Other taxes payable		1,690.4		1,683.9		6.5		1,704.8		1,698.6		6.2
Total equity		58,021.5		55,902.5		2,119.0		58,196.4		55,891.9		2,304.5

	As of September 30, 2019									As of December 31, 2018
	Three Months Ended March 31, 2020									Three Months Ended March 31, 2019
	Allergan plc			Warner Chilcott Limited			Difference			Allergan plc			Warner Chilcott Limited			Difference
Cash and cash equivalents	$	1,237.5		$	1,230.3		$	7.2		$	880.4		$	878.6		$	1.8
General and administrative expenses	$	401.3		$	398.0		$	3.3		$	308.3		$	306.1		$	2.2
Prepaid expenses and other current assets		942.3			940.7			1.6			819.1			818.7			0.4
Operating income		(1,299.6	)		(1,296.3	)		(3.3	)		(2,309.2	)		(2,307.0	)		(2.2	)
Accounts payable and accrued liabilities		5,692.2			5,690.6			1.6			4,787.2			4,787.4			(0.2	)
Interest income		21.2			21.2			-			21.3			21.3			-
Other taxes payable		1,718.4			1,713.4			5.0			1,615.5			1,615.5			-
(Loss) / income before income taxes and noncontrolling interest		(1,487.8	)		(1,484.5	)		(3.3	)		(2,475.9	)		(2,473.7	)		(2.2	)
Total equity		58,498.2			56,200.9			2,297.3			65,131.0			62,940.3			2,190.7
(Benefit) for income taxes		(1,866.8	)		(1,866.8	)		-			(68.6	)		(68.7	)		0.1
Net (loss) / income		379.0			382.3			(3.3	)		(2,407.3	)		(2,405.0	)		(2.3	)
Net (loss) / income attributable to ordinary shareholders/members		378.0			381.3			(3.3	)		(2,408.0	)		(2,405.7	)		(2.3	)

	Three Months Ended September 30, 2019									Nine Months Ended September 30, 2019
	Allergan plc			Warner Chilcott Limited			Difference			Allergan plc			Warner Chilcott Limited			Difference
General and administrative expenses	$	1,092.7		$	1,037.1		$	55.6		$	1,725.2		$	1,659.6		$	65.6
Operating (loss)		(596.6	)		(541.0	)		(55.6	)		(4,168.7	)		(4,103.1	)		(65.6	)
(Loss) before income taxes and noncontrolling interest		(767.5	)		(711.9	)		(55.6	)		(4,696.7	)		(4,631.1	)		(65.6	)
Provision for income taxes		18.1			18.2			(0.1	)		251.1			251.1			-
Net (loss)		(785.6	)		(730.1	)		(55.5	)		(4,947.8	)		(4,882.2	)		(65.6	)
Net (loss) attributable to ordinary shareholders/members		(786.8	)		(731.3	)		(55.5	)		(4,953.8	)		(4,888.2	)		(65.6	)

	Three Months Ended September 30, 2018								Nine Months Ended September 30, 2018
	Allergan plc			Warner Chilcott Limited		Difference			Allergan plc			Warner Chilcott Limited			Difference
General and administrative expenses	$	289.2		$	272.4	$	16.8		$	919.2		$	866.0		$	53.2
Operating income / (loss)		257.5			274.3		(16.8	)		(863.5	)		(810.3	)		(53.2	)
Interest income		10.0			77.3		(67.3	)		33.6			219.4			(185.8	)
Income / (loss) before income taxes and noncontrolling interest		177.1			261.2		(84.1	)		(1,264.3	)		(1,025.3	)		(239.0	)
Provision / (benefit) for income taxes		213.4			208.3		5.1			(474.0	)		(479.1	)		5.1
Net (loss) / income		(36.3	)		52.9		(89.2	)		(790.3	)		(546.2	)		(244.1	)
Dividends on preferred shares		-			-		-			46.4			-			46.4
Net (loss) / income attributable to ordinary shareholders/members		(37.9	)		51.3		(89.2	)		(842.9	)		(552.4	)		(290.5	)

The differences between general and administrative expenses in the three and nine months ended September 30, 2019 and 2018 were due to corporate related expenses incurred at Allergan plc. The differences in total equity were due to historical differences in the results of operations of the companies and differences in equity awards and dividends.

During the three and nine months ended September 30, 2018, the difference in interest income between Allergan plc and Warner Chilcott Limited was due to $0.8 billion and $9.0 billion in Receivables from the Parents and Non-current Receivables from the Parents, respectively. These Receivables related to intercompany loans between Allergan plc and subsidiaries of Warner Chilcott Limited generated related party interest income in Warner Chilcott Limited. These Receivables were contributed to the Parents during the year ended December 31, 2018 as an equity contribution and were reclassified from receivables to equity.

NOTE 3 — Summary of Significant Accounting Policies

The following are interim updates to certain of the policies described in “Note 4” of the notes to the Company’s audited consolidated financial statements for the year ended December 31, 2018 included in the Annual Report.

Implementation of New Guidance

In February 2016, the Financial Accounting Standards Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (“ASU”) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease

~~liability~~The ondifferences between general and administrative expenses in the ~~balance~~three ~~sheet~~months ~~for~~ended ~~all~~March ~~leases~~31, ~~with~~2020 aand ~~term~~2019 ~~longer~~were ~~than~~due 12to ~~months~~corporate related expenses incurred at Allergan plc. The ~~Leases~~difference ~~will~~in beaccounts ~~classified~~payable and accrued liabilities as ~~finance~~of orMarch ~~operating~~31, ~~with~~2020 ~~classification~~was ~~affecting~~due to accrued dividends. The differences in total equity were due to historical differences in the ~~pattern~~results ~~and~~of ~~classification~~operations of ~~expense~~the ~~recognition~~companies and differences in ~~the~~equity ~~income~~awards ~~statement.~~and dividends.

OnNOTE 3 — ~~January~~Summary ~~1, 2019, the Company adopted the new standard using the modified retrospective transition approach applied to all leases existing at the effective date~~ of ~~initial~~Significant ~~application~~Accounting of January 1, 2019. Prior period amounts are not adjusted and continue to be reported in accordance with historical accounting practices and the disclosures under the new standard are not required for dates and periods prior to January 1, 2019. Policies

~~When~~The ~~evaluating~~following ~~whether a contract contains a lease under the new standard, Allergan considers whether (1) the contract explicitly or implicitly identifies assets that~~ are ~~contractually~~interim ~~defined~~updates ~~and~~to ~~(2)~~certain ~~the Company obtains substantially all~~ of the ~~economic~~policies ~~benefits~~described ~~from~~in ~~the~~“Note ~~use~~4” of ~~that underlying asset and directs how and for what purpose~~ the ~~asset~~notes isto ~~used during~~ the ~~term of the contract. The~~ Company’s ~~does~~audited ~~not~~consolidated ~~have~~financial ~~the~~statements ~~right~~for ~~to use an identified asset if~~ the ~~supplier~~year ~~has~~ended ~~the~~December ~~substantive~~31, ~~right~~2019 toincluded ~~substitute~~in the ~~asset~~Annual ~~throughout the period without the Company’s approval~~Report.

~~The~~Implementation ~~new standard provides a number~~ of optional practical expedients in transition. The Company elected the ‘package of practical expedients’ which permits us not to reassess our prior conclusions about lease identification, lease classification and initial direct costs under the new ~~standard. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter was not applicable to the Company.~~guidance

~~This~~In ~~standard~~June ~~has~~2016 athe ~~significant~~FASB ~~impact~~issued onAccounting ~~our~~Standards ~~consolidated~~Update ~~balance~~(ASU) ~~sheet~~No. ~~but~~2016-13, ~~did~~Financial ~~not~~Instruments ~~have~~- aCredit ~~significant~~Losses ~~impact~~(Topic on326): ~~our~~Measurement ~~consolidated~~of ~~statements~~Credit ofLosses ~~operations~~on Financial Instruments. The ~~most~~FASB ~~significant~~subsequently ~~effects~~issued ~~relate~~amendments to ASU 2016-13, which have the ~~recognition~~same effective date and transition date of ~~ROU~~January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and ~~lease~~report ~~liabilities~~credit onlosses ~~our~~using ~~balance~~an ~~sheet~~expected ~~for~~losses ~~our~~model ~~real~~rather ~~estate~~than the incurred losses model that was previously used, and ~~fleet~~establishes ~~operating~~additional ~~leases~~disclosures related to credit risks. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which amortized cost exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.

~~Upon~~This ~~adoption~~standard became effective for us on January 1, 2020, and based on the ~~Company~~composition ~~recognized~~of ~~lease~~our ~~liabilities~~trade receivables, investment portfolio and ~~corresponding~~other ~~ROU~~financial assets, ascurrent ~~follows~~and ($forecasted ineconomic ~~millions):~~conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

	ROU Asset		Lease Liability
Real estate	$	304.2	$	370.6
Fleet		100.4		100.4
Other		57.5		77.6
Total operating leases	$	462.1	$	548.6

Risk and Uncertainties

~~The~~We ~~cumulative~~are ~~effective~~subject ~~adjustment~~to risks and uncertainties as a result of the ~~effective~~COVID-19 ~~date~~pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of ~~$22.0~~operations ~~million~~and ~~was~~financial ~~recorded~~condition, toincluding ~~opening~~sales, ~~retained~~expenses, ~~earnings~~reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain. The Company ~~has~~continues anto ~~immaterial~~monitor ~~amount~~and ofassess ~~finance~~new ~~leases~~information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets.

The ~~new~~Company's ~~standard~~medical ~~also~~aesthetic ~~provides~~portfolio ~~practical~~of ~~expedients~~products ~~for~~are ansusceptible ~~entity~~to local and national government restrictions, such as social distancing, “shelter in place” orders and business closures, due to the economic and logistical impacts these measures have on consumer demand as well as the practitioners’s ~~ongoing~~ability ~~accounting.~~to administer such procedures. The ~~Company~~inability ~~elected~~to ~~the~~perform ~~lease~~such ~~recognition~~procedures ~~exemption~~may ~~for~~cause ~~all~~customer ~~leases~~liquidity ~~with~~issues ~~lease~~resulting ~~terms~~in the inability of 12our ~~months~~customers orto ~~less~~pay receivables. ~~For~~While ~~leases~~the ~~that~~Company ~~qualify~~has ~~under~~recently ~~this~~observed, ~~exception~~particularly in certain Asia Pacific international markets, ~~the~~early ~~Company~~signs ~~will~~of ~~not~~some ~~recognize~~recovery ~~ROU~~of ~~assets~~the orglobal ~~lease~~medial ~~liabilities~~aesthetic business and ~~did~~anticipates ~~not~~that ~~recognize~~the ~~ROU~~recovery ~~assets~~will orcontinue ~~lease~~to ~~liabilities~~occur ~~for~~during ~~existing~~the ~~short-term~~second ~~leases~~half of ~~those~~2020, ~~assets~~the inextent ~~transition.~~and ~~The~~duration ~~Company~~of ~~also~~these ~~elected~~logistical impediments and any reduced demand and the ~~practical~~corresponding ~~expedient~~decreased tosales ~~not~~is ~~separate~~uncertain. Capital ~~lease~~markets and ~~non-lease~~economies ~~components~~worldwide ~~for~~have ~~leases~~also ofbeen ~~real~~negatively ~~estate,~~impacted ~~fleet~~by the COVID-19 pandemic, ITand it is possible that this can lead to a local and/or ~~office~~global ~~equipment~~economic recession. Such economic disruption could adversely effect on our business.

~~Refer~~The toseverity ~~“NOTE~~of 13the –impact ~~Leases”~~of ~~for~~the ~~further~~COVID-19 ~~information~~pandemic ~~related~~on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain. The Company's future results of operations and liquidity could be adversely impacted by reductions in sales, delays in payments of outstanding invoices beyond normal payment terms, supply chain disruptions and uncertain demand, a delay in the timing and completion of key clinical trials, and any impact on the Company’s ~~leases~~access to the capital markets. As of the date of issuance of these condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations is uncertain. Furthermore, the estimation

In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update allows for the optional reclassification of stranded tax effects resulting from the Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income to retained earnings. The amount of the reclassification is calculated as the difference between the historical and newly enacted tax rates on deferred taxes originally recorded through accumulated other comprehensive income. The Company adopted the standard as of January 1, 2019; however, due to the immaterial amount of the stranded tax effects, the Company elected not to reclassify the income tax effects from accumulated other comprehensive income to retained earnings. Tax effects unrelated to the TCJA are released from accumulated other comprehensive income using either the specific identification approach or the portfolio approach based on the nature of the underlying item.15

~~The~~process ~~Company~~required ~~adopted~~to ~~ASU~~prepare ~~2016-01,~~the ~~Financial~~Company’s ~~Instruments~~consolidated onfinancial ~~January~~statements 1,requires ~~2018.~~assumptions ~~The~~to ~~new~~be ~~standard~~made ~~required~~about ~~modified~~future ~~retrospective~~events ~~adoption~~and ~~through~~conditions ~~2018 beginning Retained Earnings~~ and ~~Accumulated~~the ~~Other~~impact ~~Comprehensive~~of ~~Income.~~COVID-19 ~~This~~on ~~was~~our ~~incorrectly~~financial ~~recorded~~results, asand awhile ~~loss~~we ~~through~~believe ~~Other~~such ~~Comprehensive~~assumptions ~~Income~~are ~~of $63.0 million during the quarter ended March 31~~reasonable, ~~2018. This~~they ~~was~~are ~~corrected~~inherently ~~during~~subjective ~~2018~~ and ~~therefore, has no impact on the annual consolidated financial statements~~uncertain. The Company’s ~~has~~actual ~~determined~~results ~~that~~could ~~the~~differ ~~adjustment~~materially ~~was~~from ~~not~~those ~~material to any previously reported interim period~~estimates. ~~The Consolidated Statement of Comprehensive (Loss) for the nine months ended September 30, 2018 has been adjusted to correct for this error.~~

Revenue Recognition

General

ASU No. 2014-09, “Revenue from Contracts with Customers” (“Topic 606”) provides that revenues are recognized when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods as specified in the underlying terms with the customer. The Company warrants products against defects and for specific quality standards, permitting the return of products under certain circumstances. Product sales are recorded net of all sales-related deductions including, but not limited to: chargebacks, trade discounts, commercial and government rebates, customer loyalty programs, fee-for-service arrangements with certain distributors, returns, and other allowances which we refer to in the aggregate as sales returns and allowances (“SRA”).

The Company’s performance obligations are primarily achieved when control of the products is transferred to the customer. Transfer of control is based on contractual performance obligations, but typically occurs upon receipt of the goods by the customer as that is when the customer has obtained control of significantly all of the economic benefits. During the three months ended March 31, 2020, the impact of COVID-19 on the Company’s SRA was not material. The Company will continue to evaluate the potential impacts of COVID-19 on the commercial and government segments, including the impact unemployment and other factors may have on commercial and government utilization rates in future periods.

Refer to “NOTE 86 – Reportable Segments” for our revenues disaggregated by product and segment and our revenues disaggregated by geography for our international segment. We believe this level of disaggregation best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.

The following table summarizes the activity from operations in the Company’s major categories of SRA ($ in millions):

	Chargebacks			Rebates			Returns and Other Allowances			Cash Discounts			Total
Balance at December 31, 2018	$	61.8		$	1,908.5		$	566.6		$	30.7		$	2,567.6
Balance at December 31, 2019	$	67.8		$	2,103.3		$	632.4		$	37.0		$	2,840.5
Provision related to sales in 2019		840.1			4,427.4			1,227.0			244.8			6,739.3
Provision related to sales in 2020		279.5			1,466.7			467.5			81.3			2,295.0
Credits and payments		(~~835~~285.16	)		(41,~~241~~485.53	)		(~~1,174~~431.93	)		(~~241~~84.24	)		(62,~~492~~286.76	)
Balance at September 30, 2019	$	66.8		$	2,094.4		$	618.7		$	34.3		$	2,814.2
Balance at March 31, 2020	$	61.7		$	2,084.7		$	668.6		$	33.9		$	2,848.9
Contra accounts receivable at September 30, 2019	$	66.8		$	94.6		$	41.7		$	34.3		$	237.4
Contra accounts receivable at March 31, 2020	$	61.7		$	72.1		$	30.0		$	33.9		$	197.7
Accounts payable and accrued expenses at September 30, 2019	$	-		$	1,999.8		$	577.0		$	-		$	2,576.8
Accounts payable and accrued expenses at March 31, 2020	$	-		$	2,012.6		$	638.6		$	-		$	2,651.2

The following table summarizes the balance sheet classification of our SRA reserves ($ in millions):

	September 30, 2019		December 31, 2018
	March 31, 2020		December 31, 2019
Contra accounts receivable	$	~~237~~197.47	$	~~207~~242.70
Accounts payable and accrued expenses		2,~~576~~651.82		2,~~359~~598.95
Total	$	2,~~814~~848.29	$	2,~~567~~840.65

The SRA provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Gross product sales	$	6,254.7		$	6,054.3		$	18,210.2		$	17,765.9
Provisions to reduce gross product sales to net product sales		(2,314.8	)		(2,214.6	)		(6,739.3	)		(6,337.0	)
Net product sales	$	3,939.9		$	3,839.7		$	11,470.9		$	11,428.9
Percentage of SRA provisions to gross sales		37.0	%		36.6	%		37.0	%		35.7	%

The SRA provisions recorded to reduce gross product sales to net product sales were as follows ($ in millions):

	Three Months Ended March 31,
	2020			2019
Gross product sales	$	5,752.0		$	5,659.9
Provisions to reduce gross product sales to net product sales		(2,295.0	)		(2,139.7	)
Net product sales	$	3,457.0		$	3,520.2
Percentage of SRA provisions to gross sales		39.9	%		37.8	%

Collectability Assessment

At the time of contract inception or customer account set-up, the Company performs a collectability assessment on the creditworthiness of such customer. The Company assesses the probability that the Company will collect the consideration to which it will be entitled in exchange for the goods sold. In evaluating collectability, the Company considers the customer’s ability and intention to pay consideration when it is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectible after sale to the customer to reflect allowances for doubtful accounts. Provision for bad debts, included in general and administrative expenses, were $1944.02 million and $03.84 million in the three months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019, respectively. ~~Provision~~ The increase in provisions for bad debts, ~~included~~over inthe ~~general~~prior ~~and~~year ~~administrative~~period ~~expenses,~~was ~~were~~primarily ~~$26.3~~related ~~million~~to ~~and~~the ~~$14.9~~impact ~~million~~of inCOVID-19 and the ~~nine~~Company’s ~~months~~assessment ~~ended~~of ~~September~~customer ~~30,~~receivables ~~2019~~primarily attributed to the US and ~~2018,~~International ~~respectively~~aesthetic business.

Goodwill and Intangible Assets with Indefinite Lives

General

The Company tests goodwill and intangible assets with indefinite lives for impairment annually in the second quarter. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a reporting unit or an indefinite lived intangible asset below its carrying amount. The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill and intangible assets, to those reporting units.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including Reporting Unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a Reporting Unit is less than its carrying amount, including goodwill. The Company may elect to bypass this qualitative assessment for some or all of its Reporting Units and perform a quantitative test as of the measurement date of the test.

Goodwill is considered impaired if the carrying amount of the net assets exceeds the fair value of the reporting unit. Impairment, if any, would be recorded in operating income / (loss) and this could result in a material impact to net income / (loss) and income / (loss) per share.

Prior to Allergan’s 2018 annual impairment test, the Company adopted the new guidance under Accounting Standard Update No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment which eliminated step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation to measure goodwill impairment loss. A goodwill impairment loss under the new guidance is instead measured using a single step test based on the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill.

Acquired in-process research and development (“IPR&D”) intangible assets represent the value assigned to research and development (“R&D”) projects acquired in a business combination that, as of the date acquired, represent the right to develop, use, sell and/or offer for sale a product or other intellectual property that has not been completed or approved. The IPR&D intangible assets are subject to impairment testing until completion or abandonment of each project. Upon abandonment, the assets are impaired if there is no future alternative use or ability to sell the asset. Impairment testing requires management to develop significant estimates and assumptions involving the determination of the fair value of the IPR&D asset, including estimated revenues, the probability of success of the project, determination of the appropriate discount rate, assessment of the asset’s life, potential regulatory risks, and net revenue growth curve assumptions. The major risks and uncertainties associated with the timely and successful completion of IPR&D projects include legal risk, market risk and regulatory risk. Changes in our assumptions could result in future impairment charges. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change or the timely completion of each project and commercial success will occur. For these and other reasons, actual results may vary significantly from estimated results.

Upon successful completion of each project and approval of a product, we will make a separate determination of the useful life of the intangible asset, transfer the amount to currently marketed products (“CMP”) and amortization expense will be recorded over the estimated useful life.

Refer to “NOTE 119 –Goodwill, Product Rights, and Other Intangible Assets” for further discussion on the Company’s goodwill and intangible assets balances and impairments.

Earnings Per Share (“EPS”)

The Company computes EPS in accordance with Accounting Standards Codification (“ASC”) Topic 260, “Earnings Per Share” (“ASC 260”) and related guidance, which requires two calculations of EPS to be disclosed: basic and diluted. Basic EPS is computed by dividing net income / (loss) by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive.

by dividing net (loss) by the weighted average ordinary shares outstanding during a period. Diluted EPS is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and restricted stock units. Ordinary share equivalents have been excluded where their inclusion would be anti-dilutive.

A reconciliation of the numerators and denominators of basic and diluted EPS follows ($ in millions, except per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Net (loss):
Net income / (loss):
Net (loss) attributable to ordinary shareholders	$	(786.8	)	$	(37.9	)	$	(4,953.8	)	$	(842.9	)
Net income / (loss) attributable to ordinary shareholders	$	378.0		$	(2,408.0	)
Basic weighted average ordinary shares outstanding		~~328~~329.01			~~339~~332.0			~~329.3~~			~~337.6~~
Basic EPS:
Net (loss) per share	$	(2.40	)	$	(0.11	)	$	(15.04	)	$	(2.50	)
Net income / (loss) per share	$	1.15		$	(7.25	)
Dividends per ordinary share	$	0.74		$	0.7274		$	~~2.22~~		$	~~2.16~~
Diluted weighted average ordinary shares outstanding		~~328~~331.09			~~339~~332.0			~~329.3~~			~~337.6~~
Diluted EPS:
Net (loss) per share	$	(2.40	)	$	(0.11	)	$	(15.04	)	$	(2.50	)
Net income / (loss) per share	$	1.14		$	(7.25	)

Stock awards to purchase 2.2 million and 1.8 million ordinary shares for the three and nine months ended September 30, 2019, respectively, were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. No shares were repurchased in the three months ended September 30, 2019. The impact of the 5.3 million shares repurchased in the nine months ended September 30, 2019 on basic EPS was 3.8 million weighted average shares. 18

Stock awards to purchase 2.74 million ~~and 2.3 million~~ ordinary shares for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018,~~2019 ~~respectively,~~ were outstanding, but not included in the computation of diluted EPS, because the awards were anti-dilutive. During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019, the Company repurchased shares under its share repurchase programs. The impact of the 25.43 million ~~and 12.0 million~~ shares repurchased in the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019 on basic EPS was 0.~~5 million and~~ 7.2 million, ~~respectively~~shares.

The Company’s preferred shares were mandatorily converted to ordinary shares on March 1, 2018. The weighted average impact of ordinary share equivalents of 3.9 million for the nine months ended September 30, 2018, which would result from the mandatory conversion of the Company’s preferred shares at the beginning of the period, were not included in the calculation of diluted EPS as their impact would be anti-dilutive.

Refer to “NOTE 16 –Shareholders’ Equity” for further discussion on the Company’s share repurchase programs.

Research and Development Activities

Research and development (“R&D”) activities are expensed as incurred and consist of self-funded R&D costs, the costs associated with work performed under collaborative R&D agreements, regulatory fees, and acquisition and license related milestone payments, if any.

18As of March 31, 2020, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs, and we additionally have products in development as part of our life-cycle management strategy for our existing product portfolio. These development projects include but are not limited to the following:

As of September 30, 2019, we are developing a number of products, some of which utilize novel drug delivery systems, through a combination of internal and collaborative programs, and we additionally have products in development as part of our life-cycle management strategy for our existing product portfolio. These development projects include but are not limited to the following:

Product	Therapeutic Area	Indication	Expected Launch Year	Phase
Abicipar	Eye Care	Age Related Macular Degeneration	2020	Review
Atogepant	Central Nervous System	Prophylaxis Migraine	2021	III
Presbysol	Eye Care	Presbyopia	2022	III
Cenicriviroc	Gastrointestinal	NASH	2022	III
Brimonidine DDS	Eye Care	Geographic Atrophy	2024	II
Relamorelin	Gastrointestinal	Gastroparesis	2024	III
Botox	Medical Aesthetics	Platysma/Masseter	2025/2024	II
Abicipar	Eye Care	Diabetic Macular Edema	2025	II

Product	Therapeutic Area	Indication	Expected Launch Year	Phase
Cariprazine	Central Nervous System	Bipolar Depression	2019	Approved
Ubrogepant	Central Nervous System	Acute Migraine	2020	Review
Bimatoprost SR	Eye Care	Glaucoma	2020	Review
Abicipar	Eye Care	Age Related Macular Degeneration	2020	Review
Atogepant	Central Nervous System	Prophylaxis Migraine	2021	III
Presbysol	Eye Care	Presbyopia	2021	III
Cenicriviroc	Gastrointestinal	NASH	2022	III
Brimonidine DDS	Eye Care	Geographic Atrophy	2023	II
Relamorelin	Gastrointestinal	Gastroparesis	2024	III
Botox	Medical Aesthetics	Platysma/Masseter	2025/2024	II
Abicipar	Eye Care	Diabetic Macular Edema	2025	II

On March 5, 2020, the Company received FDA approval for Durysta™ (bimatoprost SR), a single intracameral, biodegradable sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

As of March 31, 2020, the Company has not experienced a material delay in clinical trials for its R&D projects due to COVID-19 although there could be delays in the future depending on the duration and impact of COVID-19. In addition to the projects listed in the table above, the Company continues to develop brazikumab, a gastrointestinal development project for indications of Crohn’s disease and ulcerative colitis. InOn January 27, 2020, in connection with the ~~proposed~~ AbbVie Transaction, ~~the~~Allergan ~~Company~~announced isthat ~~actively~~it ~~seeking~~entered into definitive agreements to divest the global development and commercial rights of brazikumab,. This agreement was made in conjunction with ~~any~~the ~~such~~regulatory approval process for the AbbVie Transaction. The closing of the divestiture of brazikumab is contingent onupon the closing of the AbbVie Transaction. and the satisfaction of other customary closing conditions.

Recent Accounting Pronouncements

In ~~November~~March ~~2018~~2020, the FASB issued ASU No. ~~2018~~2020-1804, ~~Collaborative~~Reference ~~Arrangements~~Rate Reform (Topic ~~808~~848): ~~Clarifying~~that ~~the~~provides ~~Interaction~~elective ~~Between~~optional ~~Topic~~expedients ~~808~~ and ~~Topic~~exceptions ~~606. The~~to ~~ASU~~existing ~~provides~~accounting ~~more~~requirements ~~comparability~~for inentities ~~the~~that ~~presentation~~have ofcontracts, ~~revenue~~hedging ~~for~~relationships, ~~certain~~and other transactions ~~between~~that ~~collaborative~~reference ~~arrangement~~LIBOR ~~participants~~or ~~and~~another ~~only~~reference ~~allows~~rate aexpected ~~company~~ to ~~present~~be ~~units~~discontinued because of ~~account~~reference inrate ~~collaborative~~reform ~~arrangements~~if ~~that~~certain criteria are ~~within~~met. The ~~the~~ASU ~~scope~~is ofeffective ~~the~~as ~~revenue~~of ~~recognition~~March ~~standard~~12, ~~together~~2020 ~~with~~through ~~revenue~~December ~~accounted~~31, ~~for~~2022. The ~~under~~expedients ~~the~~and ~~revenue~~exceptions ~~recognition~~provided ~~standard.~~by ~~The~~this ~~parts~~ASU ofdo ~~the~~not ~~collaborative~~apply ~~arrangement~~to ~~that~~contract ~~are~~modifications ~~not~~made inand ~~the~~hedging ~~scope~~relationships ofentered ~~the~~into ~~revenue~~or ~~recognition~~evaluated ~~standard~~after ~~should~~December be31, ~~presented~~2022, ~~separately~~except ~~from~~for ~~revenue~~hedging ~~accounted~~relationships ~~for~~existing ~~under~~as ~~the~~of ~~revenue~~December ~~recognition~~31, ~~standard. The~~2022, ~~amendments~~that inan ~~ASU~~entity ~~No.~~has ~~2018-18~~elected ~~are~~certain ~~effective~~optional expedients for ~~fiscal~~and ~~years~~that ~~beginning~~are ~~after~~retained ~~December~~through ~~15,~~the ~~2019,~~end ~~and~~of ~~interim~~the ~~periods~~hedging ~~within~~relationship. ~~those~~As ~~fiscal~~of ~~years. The~~March ~~adoption~~31, of2020, this ~~guidance~~ASU isdoes not ~~anticipated to~~ have a material impact on ~~the~~our ~~Company’s~~ financial position and results of operations.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40), relating to a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by a vendor (i.e., a service contract). Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application is permitted. The Company will adopt the new guidance prospectively to eligible costs incurred on or after the date this guidance is first applied. The adoption of this guidance is not anticipated to have a material impact on the Company’s financial position and results of operations.

In August 2018, the FASB issued ASU No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20) – Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The revisions to the disclosure requirements affect only the year-end financial statements of plan sponsors, as there are no changes related to interim financial statements. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted. The ASU provisions will be applied on a retrospective basis to all periods presented. This pronouncement only has an impact to disclosure requirements and does not have an impact on our financial position or results of operations.

InNOTE ~~August~~4 ~~2018,~~– ~~the~~Other ~~FASB~~Income ~~issued~~/ ~~ASU No. 2018-13, Fair Value Measurement~~ (~~Topic 820~~Expense): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, and the valuation processes of Level 3 fair value measurements. However, the Company will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements, and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective date. The Company is permitted to early adopt either the entire ASU or only the provisions that eliminate or modify the requirements. This pronouncement only has an impact to disclosure requirements and does not have an impact on our financial position or results of operations.

NOTE 4 — Business Transactions

2019 Transactions

The following transaction was announced and completed in the nine months ended September 30, 2019.

Envy Medical, Inc.

On March 26, 2019, the Company acquired Envy Medical, Inc. (“Envy”), a privately held medical aesthetics company that specializes in non-surgical, non-invasive skin resurfacing systems for an acquisition accounting purchase price of $81.4 million, which includes $67.4 million of product rights and other intangibles, $34.1 million of goodwill and other assets and liabilities. The transaction was treated as a business combination. The acquisition combines Envy’s skin care product portfolio with the Company’s leading medical aesthetics business.

NOTE 5 — Assets Held for Sale

The following represents the assets held for sale ($ in millions):

	September 30,		December 31,
	2019		2018
Assets held for sale:
Inventories	$	-	$	34.0
Property, plant and equipment, net		32.5		32.8
Product rights and other intangibles		-		849.4
Total assets held for sale	$	32.5	$	916.2

As of December 31, 2018, the Company had concluded that its Anti-Infectives business met the criteria for held for sale based on management’s intent and ability to divest the business within the next twelve months. Assets held for sale also include miscellaneous properties. As of June 30, 2019, and as a result of the proposed AbbVie Transaction, the Company concluded that the Anti-Infectives business no longer met the criteria for held for sale. The Anti-Infectives intangible assets and inventory were reclassified to held in use at the lower of their carrying amount before the assets were recorded as held for sale less any amortization that would have been recognized had the assets been continuously classified as held and used or their fair value at the date of the subsequent decision not to sell. As a result of the reclassification, the Company recorded a charge of $129.6 million, primarily related to amortization that would have been recorded if the assets were held and used, within Assets, sales and impairments, net for the nine month period the assets were held for sale.

NOTE 6 – Other Income / (Expense)

Other income, net consisted of the following ($ in millions):

	Three Months Ended September 30,						Nine Months Ended September 30,
	Three Months Ended March 31,
	2019			2018			2019			2018
	2020			2019
Teva Share Activity	$	-		$	-		$	-		$	60.9
Debt extinguishment other		-			(0.3	)
Sale of businesses		-			129.6			-			182.6
Other income, net		(24.9	)		14.1
Debt extinguishment other		-			(8.3	)		(0.2	)		0.8
Other income, net	$	(24.9	)	$	13.8
Other income, net		2.5			8.7			11.8			22.3
Other income, net	$	2.5		$	130.0		$	11.6		$	266.6

Teva Share Activity

During the nine months ended September 30, 2018, the Company recorded the following movements in its investment in Teva securities (“Teva Share Activity”) ($ in millions except per share information):

	Shares			Carrying Value per Share		Market Price			Proceeds Received		Value of Marketable Securities			Unrealized Gain / (Loss) as a Component of Other Comprehensive Income			Gain / (Loss) Recognized in Other Income/ (Expense), Net		Derivative Instrument (Liability)/ Asset			Retained Earnings
Teva securities as of December 31, 2017		95.9		$	17.60	$	18.95		n.a.		$	1,817.7		$	129.3		$	-	$	(62.9	)	$	-
Impact of ASU No. 2016-01 during the three months ended March 31, 2018		-			-		-			-		-			(129.3	)		-		-			129.3
Settlement of initial accelerated share repurchase ("ASR"), net during the three months ended March 31, 2018		(25.0	)		18.95		16.53	*		413.3		(473.8	)		-			2.5		62.9			-
Settlement of forward sale entered into during the three months ended March 31, 2018, net		(25.0	)		17.09		18.61	**		465.5		(427.3	)		-			38.2		-			-
Open market sales during the nine months ended September 30, 2018		(45.9	)	n.a.			20.41			936.7		(916.6	)		-			20.2		-			-
Teva securities as of and for the nine months ended September 30, 2018		-		$	-	$	-		$	1,815.5	$	-		$	-		$	60.9	$	-		$	129.3
* Market price represented average price over the life of the contract. On the January 17, 2018 settlement date, the closing stock price of Teva securities was $21.48.
**Market price represented average price over the life of the contract. On the May 7, 2018 settlement date, the closing stock price of Teva securities was $18.62.

Sale of Businesses

During the three and nine months ended September 30, 2018, the Company recorded a net gain of $129.6 million as a result of the sale of five medical dermatology products to Almirall, S.A.

During the nine months ended September 30, 2018, the Company completed the sale of a non-strategic asset group that qualified as a business, for $55.0 million in cash plus deferred consideration of $20.0 million. As a result of this transaction, the Company recognized a gain of $53.0 million.

Debt Extinguishment Other

During the nine months ended September 30, 2019, the Company repurchased $249.8 million of senior notes in the open market. The net gain / (loss) on the debt extinguishments was not material.

During the three and nine months ended September 30, 2018, the Company repurchased $1,767.2 million and $2,223.1 million, respectively, of senior notes in the open market. During the three months ended September 30, 2018, as a result of the debt extinguishment, the Company recognized a net loss of $8.3 million, within “Other income / (expense), net” for the discount received upon repurchase of $5.1 million, offset by the non-cash write-off of premiums and debt fees related to the repaid notes of $13.4 million. During the nine months ended September 30, 2018, as a result of the debt extinguishment, the Company recognized a net gain of $0.8 million within “other income / (expense), net” for the discount received upon repurchase of $18.2 million, offset by the non-cash write-off of premiums and debt fees related to the repaid notes of $17.4 million.

During the three and nine months ended September 30, 2019 and 2018, the Company redeemed and retired the following senior notes ($ in millions):

	Three Months Ended September 30, 2019				Nine Months Ended September 30, 2019
Tranche	Face Value Retired		Cash Paid for Retirement		Face Value Retired		Cash Paid for Retirement		Remaining Face Value at September 30, 2019
3.000% due 2020	$	-	$	-	$	180.7	$	180.7	$	2,526.0
3.450% due 2022		-		-		62.3		62.3		2,878.2
3.800% due 2025		-		-		6.8		6.8		3,020.7
Total	$	-	$	-	$	249.8	$	249.8	$	8,424.9

	Three Months Ended September 30, 2018				Nine Months Ended September 30, 2018
Tranche	Face Value Retired		Cash Paid for Retirement		Face Value Retired		Cash Paid for Retirement		Remaining Face Value at September 30, 2018
2.450% due 2019	$	-	$	-	$	8.8	$	8.8	$	491.2
3.000% due 2020		408.6		407.8		449.3		448.4		3,050.6
3.450% due 2022		-		-		59.5		58.6		2,940.5
3.850% due 2024		52.1		52.0		63.3		62.9		1,136.7
3.800% due 2025		787.5		784.4		872.5		867.0		3,127.5
4.550% due 2035		345.0		344.7		460.0		454.8		2,040.0
4.850% due 2044		140.1		139.5		199.1		196.8		1,300.9
4.750% due 2045		33.9		33.7		110.6		107.6		1,089.4
Total	$	1,767.2	$	1,762.1	$	2,223.1	$	2,204.9	$	15,176.8

Other Income, Net

Other income, net includes the mark to market losses of $57.18 million and mark to market gains of $110.94 million~~, respectively,~~ on equity securities held by the Company during the three ~~and nine~~ months ended ~~September~~March 3031, 2020 and March 31, 2019, respectively.

NOTE 75 — Share-Based Compensation

The Company recognizes compensation expense for all share-based compensation awards made to employees and directors based on the fair value of the awards on the date of grant.

The Company grants awards with the following features:

•

Time-based restricted stock and restricted stock unit awards (including, in certain foreign jurisdictions, cash-settled restricted stock unit awards, which are recorded as a liability);

•

Performance-based restricted stock unit awards measured against performance-based targets defined by the Company, including, but not limited to, total shareholder return metrics and R&D milestones, as defined by the Company; and

•

Non-qualified options to purchase outstanding shares.

The Company recognizes share-based compensation expense for granted awards over the applicable vesting period.

Fair Value Assumptions

All restricted stock and restricted stock units (whether time-based or performance-based) are granted and expensed using the fair value per share on the applicable grant date, over the applicable vesting period. Non-qualified options to purchase ordinary shares are granted to employees at exercise prices per share equal to the closing market price per share on the date of grant. The fair value of non-qualified options is determined on the applicable grant dates using the Black-Scholes method of valuation and that amount is recognized as an expense over the vesting period. Using the Black-Scholes valuation model, the fair value of options is based on the following assumptions:

	2019 Grants	~~2018 Grants~~
Dividend yield	1.7 - 12.82%	~~1.5%~~
Expected volatility	23.5 - 26.4%	~~27.0%~~
Risk-free interest rate	1.9 - 2.6%	~~2.2 - 2.9%~~
Expected term (years)	7.0	~~7.0~~

Share-Based Compensation Expense

Share-based compensation expense recognized in the Company’s results of operations for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2019~~2020 and ~~2018~~2019 was as follows ($ in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	Three Months Ended March 31,
	2019		2018		2019		2018
	2020		2019
Equity-based compensation awards	$	4951.96	$	5752.83	$	~~161.7~~	$	~~185.2~~
Total share-based compensation expense	$	4951.96	$	5752.83	$	~~161.7~~	$	~~185.2~~

Unrecognized future share-based compensation expense was $~~354~~477.90 million as of ~~September~~March 3031, ~~2019~~2020. This amount will be recognized as an expense over a remaining weighted average period of 1.58 years. Share-based compensation is being amortized and charged to operations over the same period as the restrictions are eliminated for the participants, which is generally on a straight-line basis.

Share Activity

The following is a summary of equity award activity for unvested restricted stock and stock units in the period from December 31, ~~2018~~2019 through ~~September~~March 3031, ~~2019~~2020 (in millions, except per share data):

	Shares			Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (Years)		Aggregate Grant Date Fair Value
Restricted shares / units outstanding at December 31, 2018		2.5		$	190.27		1.6	$	472.9
Restricted shares / units outstanding at December 31, 2019		3.1		$	159.74		1.4	$	493.0
Granted		1.53			~~140~~193.1184				~~210~~257.58
Vested		(0.78	)		~~209~~174.7087				(~~141~~143.52	)
Forfeited		~~(0.1~~-	)		~~176~~164.4537				(264.69	)
Restricted shares / units outstanding at September 30, 2019		3.2		$	161.17		1.6	$	515.3
Restricted shares / units outstanding at March 31, 2020		3.6		$	168.76		1.9	$	602.7

The following is a summary of equity award activity for non-qualified options to purchase ordinary shares in the period from December 31, ~~2018~~2019 through ~~September~~March 3031, ~~2019~~2020 (in millions, except per share data):

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, vested and expected to vest at December 31, 2018		6.3		$	122.74		4.4	$	69.0
Outstanding, vested and expected to vest at December 31, 2019		5.5		$	127.27		3.9	$	352.9
Granted		~~0.3~~-			~~140.56~~-
Exercised		(0.56	)		91108.4513
Cancelled		~~(0.1~~-	)		~~220~~229.6140
Outstanding, vested and expected to vest at September 30, 2019		6.0		$	125.55		4.0	$	255.5
Outstanding, vested and expected to vest at March 31, 2020		4.9		$	128.56		3.9	$	238.6

~~The increase in the aggregate intrinsic value of the options is primarily related to an increase in the Company’s stock from $133.66 as of December 31, 2018 to $168.29 as of September 30, 2019.~~21

NOTE 86 — Reportable Segments

The Company’s businesses are organized into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments. During the second quarter of 2019, the Company changed the operational and management structure for its in-development calcitonin gene-related peptide (“CGRP”) receptors, Ubrogepant and Atogepant. These development products were previously reported within the US Specialized Therapeutics segment and have been transferred to the US General Medicine segment to align these development products with the management structure and reporting. The revenues and cost of sales related to these products in the prior periods were zero and any selling and marketing expenses and general and administrative expenses were de minimis and therefore it was not necessary to recast prior periods.

The operating segments are organized as follows:

• The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the U.S., including Medical Aesthetics, ~~Medical Dermatology through September 20, 2018,~~ Eye Care and Neuroscience and Urology therapeutic products.

•

The US General Medicine segment includes sales and expenses relating to branded products within the U.S. that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands.

•

The International segment includes sales and expenses relating to products sold outside the U.S.

The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level:

•

Revenues and operating expenses within cost of sales, selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, divestitures, acquisitions, certain milestones and other shared costs.

•

General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States.

•

Other select revenues and operating expenses including R&D expenses, amortization, IPR&D impairments, goodwill impairments and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.

•

Total assets including capital expenditures.

The Company defines segment net revenues as product sales and other revenue derived from our products or licensing agreements.

Cost of sales within segment contribution includes standard production and packaging costs for the products we manufacture, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales within segment contribution excludes non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles.

Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs.

General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation costs and professional services costs which are general in nature and attributable to the segment.

~~Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and nine months ended September 30, 2019 and 2018 ($ in millions):~~ 22

	Three Months Ended September 30, 2019
	US Specialized Therapeutics			US General Medicine			International			Total
Net revenues	$	1,670.8		$	1,518.6		$	835.1		$	4,024.5
Operating expenses:
Cost of sales(1)		151.1			245.2			144.6			540.9
Selling and marketing		389.5			261.2			226.9			877.6
General and administrative		50.1			45.0			26.0			121.1
Segment contribution	$	1,080.1		$	967.2		$	437.6		$	2,484.9
Contribution margin		64.6	%		63.7	%		52.4	%		61.7	%
Corporate(2)											1,067.3
Research and development											474.5
Amortization											1,537.7
Asset sales and impairments, net											2.0
Operating (loss)										$	(596.6	)
Operating margin											(14.8	)%
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
(2) Corporate includes net revenues of $26.2 million.

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three months ended March 31, 2020 and 2019 ($ in millions):

	Three Months Ended March 31, 2020
	US Specialized Therapeutics			US General Medicine			International			Total
Net revenues	$	1,541.5		$	1,320.5		$	691.4		$	3,553.4

Operating expenses:
Cost of sales⁽¹⁾		129.7			250.6			117.4			497.7
Selling and marketing		420.4			296.4			210.7			927.5
General and administrative		59.0			50.2			36.3			145.5
Segment contribution	$	932.4		$	723.3		$	327.0		$	1,982.7
Contribution margin		60.5	%		54.8	%		47.3	%		55.8	%
Corporate⁽²⁾											374.8
Research and development											430.0
Goodwill impairment											913.0
Amortization											1,416.4
Asset sales and impairments, net											148.1
Operating (loss)										$	(1,299.6	)
Operating margin											(36.6	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Corporate includes net revenues of $51.0 million.

	Three Months Ended March 31, 2019
	US Specialized Therapeutics			US General Medicine			International			Total
Net revenues	$	1,542.9		$	1,249.9		$	801.5		$	3,594.3

Operating expenses:
Cost of sales⁽¹⁾		120.1			190.5			109.7			420.3
Selling and marketing		356.8			210.5			237.6			804.9
General and administrative		54.6			43.8			25.7			124.1
Segment contribution	$	1,011.4		$	805.1		$	428.5		$	2,245.0
Contribution margin		65.6	%		64.4	%		53.5	%		62.5	%
Corporate⁽²⁾											258.0
Research and development											435.0
Goodwill impairment											2,467.0
Amortization											1,399.4
Asset sales and impairments, net											(5.2	)
Operating (loss)										$	(2,309.2	)
Operating margin											(64.2	)%

⁽¹⁾Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
⁽²⁾Corporate includes net revenues of $2.8 million.

The following table presents our net revenue disaggregated by geography for our international segment for the three months ended March 31, 2020 and 2019 ($ in millions):

	Three Months Ended March 31,
	2020		2019
Europe	$	323.0	$	354.4
Asia Pacific, Middle East and Africa		182.8		250.7
Latin America and Canada		161.8		178.2
Other*		23.8		18.2
Total International	$	691.4	$	801.5
*Includes royalty and other revenue

The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the three months ended March 31, 2020 and 2019 ($ in millions):

	Three Months Ended March 31, 2020
	US Specialized Therapeutics		US General Medicine		International		Total
Botox^®	$	608.5	$	-	$	203.7	$	812.2
Restasis^®		278.6		-		11.3		289.9
Vraylar^®		-		277.3		-		277.3
Juvederm^® Collection		107.5		-		113.1		220.6
Linzess^®/Constella^®		-		172.2		7.1		179.3
Lumigan^®/Ganfort^®		63.0		-		80.7		143.7
Bystolic^® / Byvalson^®		-		129.8		0.5		130.3
Alphagan^®/Combigan^®		81.6		-		36.9		118.5
Eye Drops		66.5		-		50.9		117.4
Lo Loestrin^®		-		109.8		-		109.8
Alloderm ^®		102.1		-		1.7		103.8
Ozurdex ^®		29.9		-		63.8		93.7
Viibryd^®/Fetzima^®		-		89.8		3.5		93.3
Zenpep^®		-		65.6		0.4		66.0
Armour Thyroid		-		46.3		-		46.3
Breast Implants		40.1		-		5.2		45.3
Skin Care		38.5		-		2.8		41.3
Viberzi^®		-		37.3		0.4		37.7
Coolsculpting ^® Systems & Add On Applicators		36.2		-		1.4		37.6
Teflaro^®		-		35.0		1.5		36.5
Coolsculpting ^® Consumables		22.7		-		8.8		31.5
Saphris^®		-		31.0		-		31.0
Dalvance^®		-		23.0		3.1		26.1
Liletta^®		-		23.1		-		23.1
Carafate ^® / Sulcrate ^®		-		19.0		1.0		20.0
Savella^®		-		19.3		-		19.3
Namzaric^®		-		17.8		-		17.8
Avycaz^®		-		11.8		-		11.8
Canasa^®/Salofalk^®		-		7.2		4.0		11.2
Ubrelvy^®		-		11.1		-		11.1
Asacol^®/Delzicol^®		-		2.6		7.7		10.3
Kybella^® / Belkyra^®		5.3		-		0.1		5.4
Aczone^®		3.0		-		-		3.0
Namenda^®		-		2.9		-		2.9
Rapaflo^®		1.4		-		1.1		2.5
Other		56.6		188.6		80.7		325.9
Total segment revenues	$	1,541.5	$	1,320.5	$	691.4	$	3,553.4
Corporate revenues								51.0
Total net revenues							$	3,604.4

	Nine Months Ended September 30, 2019
	Three Months Ended March 31, 2019
	US Specialized Therapeutics			US General Medicine			International			Total
Net revenues	$	4,998.8		$	4,224.2		$	2,484.3		$	11,707.3
Botox®	$	627.1		$	-		$	241.3		$	868.4
Operating expenses:
Juvederm® Collection		129.7			-			157.8			287.5
Cost of sales(1)		422.2			667.0			399.9			1,489.1
Restasis®		231.7			-			10.4			242.1
Selling and marketing		1,114.3			721.8			718.1			2,554.2
Linzess®/Constella®		-			161.3			5.5			166.8
General and administrative		142.3			119.2			80.1			341.6
Vraylar®		-			143.7			-			143.7
Segment contribution	$	3,320.0		$	2,716.2		$	1,286.2		$	7,322.4
Lumigan®/Ganfort®		57.7			-			85.1			142.8
Contribution margin		66.4	%		64.3	%		51.8	%		62.5	%
Bystolic® / Byvalson®		-			128.3			0.4			128.7
Corporate(2)											1,677.5
Lo Loestrin®		-			125.8			-			125.8
Research and development											1,359.5
Alphagan®/Combigan®		83.0			-			37.6			120.6
Amortization											4,339.1
Eye Drops		49.4			-			55.4			104.8
Goodwill impairments											3,552.8
Alloderm ®		95.0			-			1.6			96.6
In-process research and development impairments											436.0
Ozurdex ®		30.3			-			63.1			93.4
Asset sales and impairments, net											126.2
Viibryd®/Fetzima®		-			85.0			2.1			87.1
Operating (loss)										$	(4,168.7	)
Breast Implants		61.2			-			11.2			72.4
Operating margin											(35.6	)%
Coolsculpting ® Consumables		47.8			-			17.8			65.6
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
Zenpep®		-			63.0			-			63.0
(2) Corporate includes net revenues of $30.6 million.
Carafate ® / Sulcrate ®		-			54.3			0.6			54.9
Armour Thyroid		-			50.0			-			50.0
Viberzi®		-			37.2			0.3			37.5
Skin Care		34.7			-			2.7			37.4
Asacol®/Delzicol®		-			24.7			10.3			35.0
Teflaro®		-			33.5			0.2			33.7
Saphris®		-			31.9			-			31.9
Avycaz®		-			29.7			-			29.7
Coolsculpting ® Systems & Add On Applicators		15.1			-			10.6			25.7
Namzaric®		-			23.4			-			23.4
Savella®		-			20.7			-			20.7
Liletta®		-			14.8			-			14.8
Canasa®/Salofalk®		-			10.2			3.6			13.8
Rapaflo®		11.8			-			0.6			12.4
Dalvance®		-			12.0			-			12.0
Namenda®		-			9.5			-			9.5
Kybella® / Belkyra®		7.3			-			1.6			8.9
Aczone®		1.6			-			-			1.6
Other		59.5			190.9			81.7			332.1
Total segment revenues	$	1,542.9		$	1,249.9		$	801.5		$	3,594.3
Corporate revenues											2.8
Total net revenues										$	3,597.1

	Three Months Ended September 30, 2018
	US Specialized Therapeutics			US General Medicine			International			Total
Net revenues	$	1,706.2		$	1,381.3		$	821.6		$	3,909.1
Operating expenses:
Cost of sales(1)		143.0			219.6			130.7			493.3
Selling and marketing		313.7			233.2			206.0			752.9
General and administrative		47.3			37.7			35.1			120.1
Segment contribution	$	1,202.2		$	890.8		$	449.8		$	2,542.8
Contribution margin		70.5	%		64.5	%		54.7	%		65.0	%
Corporate(2)											273.0
Research and development											424.2
Amortization											1,588.5
Asset sales and impairments, net											(0.4	)
Operating income										$	257.5
Operating margin											6.6	%
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
(2) Corporate includes net revenues of $2.3 million.

As previously described, the closing of the divestiture of Zenpep^® is contingent upon the closing of the AbbVie Transaction and the satisfaction of other customary closing conditions.

	Nine Months Ended September 30, 2018
	US Specialized Therapeutics			US General Medicine			International			Total
Net revenues	$	5,111.5		$	3,925.0		$	2,634.5		$	11,671.0
Operating expenses:
Cost of sales(1)		425.9			604.0			391.0			1,420.9
Selling and marketing		970.2			713.5			697.9			2,381.6
General and administrative		145.6			111.3			100.4			357.3
Segment contribution	$	3,569.8		$	2,496.2		$	1,445.2		$	7,511.2
Contribution margin		69.8	%		63.6	%		54.9	%		64.4	%
Corporate(2)											733.1
Research and development											1,588.1
Amortization											4,983.2
In-process research and development impairments											798.0
Asset sales and impairments, net											272.3
Operating (loss)										$	(863.5	)
Operating margin											(7.4	)%
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results.
(2) Corporate includes net revenues of $36.7 million.

NOTE 7 — Inventories

The following table presents our net revenue disaggregated by geography for our international segment for the three and nine months ended September 30, 2019 and 2018 ($ in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Europe	$	346.5	$	329.8	$	1,087.1	$	1,141.5
Asia Pacific, Middle East and Africa		266.9		272.4		779.1		796.8
Latin America and Canada		199.9		203.3		560.2		646.2
Other*		21.8		16.1		57.9		50.0
Total International	$	835.1	$	821.6	$	2,484.3	$	2,634.5
*Includes royalty and other revenue

The following tables present global net revenues for the top products greater than 10% of total revenues of the Company as well as a reconciliation of segment revenues to total net revenues for the three and nine months ended September 30, 2019 and 2018 ($ in millions):

	Three Months Ended September 30, 2019
	US Specialized Therapeutics		US General Medicine		International		Total
Botox®	$	669.2	$	-	$	259.5	$	928.7
Restasis®		286.8		-		9.2		296.0
Juvederm® Collection		134.8		-		144.7		279.5
Vraylar®		-		234.6		-		234.6
Linzess®/Constella®		-		214.7		6.7		221.4
Lo Loestrin®		-		161.4		-		161.4
Lumigan®/Ganfort®		67.5		-		89.7		157.2
Bystolic® / Byvalson®		-		152.2		0.6		152.8
Alphagan®/Combigan®		90.9		-		40.4		131.3
Eye Drops		62.0		-		63.8		125.8
Viibryd®/Fetzima®		-		105.1		3.0		108.1
Ozurdex ®		33.7		-		63.8		97.5
Alloderm ®		95.0		-		2.1		97.1
Zenpep®		-		74.2		0.7		74.9
Breast Implants		58.5		-		5.7		64.2
Coolsculpting ® Consumables		40.4		-		21.6		62.0
Carafate ® / Sulcrate ®		-		55.1		0.8		55.9
Armour Thyroid		-		54.4		-		54.4
Viberzi®		-		50.1		0.6		50.7
Teflaro®		-		38.4		2.1		40.5
Skin Care		36.1		-		4.0		40.1
Saphris®		-		34.5		-		34.5
Avycaz®		-		29.6		-		29.6
Dalvance®		-		23.2		1.4		24.6
Coolsculpting ® Systems & Add On Applicators		12.6		-		11.4		24.0
Savella®		-		24.0		-		24.0
Namzaric®		-		22.4		-		22.4
Liletta®		-		19.9		-		19.9
Asacol®/Delzicol®		-		11.9		7.2		19.1
Canasa®/Salofalk®		-		5.8		4.4		10.2
Rapaflo®		5.2		-		1.5		6.7
Kybella® / Belkyra®		5.3		-		0.3		5.6
Namenda®		-		4.0		-		4.0
Aczone®		3.4		-		-		3.4
Other		69.4		203.1		89.9		362.4
Total segment revenues	$	1,670.8	$	1,518.6	$	835.1	$	4,024.5
Corporate revenues								26.2
Total net revenues							$	4,050.7

	Nine Months Ended September 30, 2019
	US Specialized Therapeutics		US General Medicine		International			Total
Botox®	$	1,995.7	$	-	$	775.4		$	2,771.1
Juvederm® Collection		421.1		-		475.2			896.3
Restasis®		829.4		-		31.5			860.9
Linzess®/Constella®		-		572.0		17.0			589.0
Vraylar®		-		574.4		-			574.4
Lumigan®/Ganfort®		187.3		-		265.2			452.5
Lo Loestrin®		-		432.7		-			432.7
Bystolic® / Byvalson®		-		431.0		1.5			432.5
Alphagan®/Combigan®		265.5		-		118.9			384.4
Eye Drops		169.2		-		176.5			345.7
Viibryd®/Fetzima®		-		297.9		7.8			305.7
Ozurdex ®		93.9		-		207.9			301.8
Alloderm ®		291.2		-		5.9			297.1
Coolsculpting ® Consumables		148.9		-		59.7			208.6
Zenpep®		-		207.2		0.7			207.9
Breast Implants		187.3		-		(14.5	)		172.8
Carafate ® / Sulcrate ®		-		165.6		2.1			167.7
Armour Thyroid		-		161.1		-			161.1
Viberzi®		-		138.1		1.2			139.3
Skin Care		113.4		-		10.4			123.8
Teflaro®		-		108.9		2.3			111.2
Saphris®		-		99.0		-			99.0
Asacol®/Delzicol®		-		68.2		27.2			95.4
Avycaz®		-		86.0		-			86.0
Coolsculpting ® Systems & Add On Applicators		45.9		-		33.6			79.5
Namzaric®		-		68.4		-			68.4
Savella®		-		67.0		-			67.0
Dalvance®		-		55.5		3.6			59.1
Liletta®		-		56.6		-			56.6
Canasa®/Salofalk®		-		24.0		12.1			36.1
Rapaflo®		21.5		-		3.5			25.0
Kybella® / Belkyra®		21.1		-		2.5			23.6
Namenda®		-		19.6		-			19.6
Aczone®		6.8		-		-			6.8
Other		200.6		591.0		257.1			1,048.7
Total segment revenues	$	4,998.8	$	4,224.2	$	2,484.3		$	11,707.3
Corporate revenues									30.6
Total net revenues								$	11,737.9

	Three Months Ended September 30, 2018
	US Specialized Therapeutics		US General Medicine		International		Total
Botox®	$	623.4	$	-	$	256.3	$	879.7
Restasis®		298.0		-		13.6		311.6
Juvederm® Collection		127.2		-		138.6		265.8
Linzess®/Constella®		-		204.8		5.7		210.5
Lumigan®/Ganfort®		78.0		-		94.8		172.8
Bystolic® / Byvalson®		-		151.2		0.5		151.7
Lo Loestrin®		-		141.5		-		141.5
Vraylar®		-		138.0		-		138.0
Alphagan®/Combigan®		95.4		-		40.5		135.9
Eye Drops		54.8		-		66.8		121.6
Alloderm ®		105.8		-		1.0		106.8
Breast Implants		58.2		-		35.6		93.8
Viibryd®/Fetzima®		-		88.5		1.8		90.3
Coolsculpting ® Consumables		55.5		-		14.2		69.7
Zenpep®		-		62.1		-		62.1
Ozurdex ®		28.6		-		25.8		54.4
Carafate ® / Sulcrate ®		-		53.4		0.7		54.1
Canasa®/Salofalk®		-		46.8		4.4		51.2
Armour Thyroid		-		48.0		-		48.0
Viberzi®		-		46.8		0.3		47.1
Asacol®/Delzicol®		-		32.1		10.9		43.0
Coolsculpting ® Systems & Add On Applicators		29.4		-		8.3		37.7
Saphris®		-		36.4		-		36.4
Skin Care		32.2		-		3.7		35.9
Teflaro®		-		33.4		-		33.4
Namzaric®		-		28.0		-		28.0
Avycaz®		-		24.7		-		24.7
Savella®		-		22.4		-		22.4
Rapaflo®		20.5		-		1.8		22.3
Aczone®		17.4		-		0.1		17.5
Namenda®		-		16.3		-		16.3
Liletta®		-		12.7		-		12.7
Dalvance®		-		9.2		-		9.2
Kybella® / Belkyra®		5.2		-		1.6		6.8
Other		76.6		185.0		94.6		356.2
Total segment revenues	$	1,706.2	$	1,381.3	$	821.6	$	3,909.1
Corporate revenues								2.3
Total net revenues							$	3,911.4

	Nine Months Ended September 30, 2018
	US Specialized Therapeutics		US General Medicine		International		Total
Botox®	$	1,854.4	$	-	$	777.1	$	2,631.5
Restasis®		872.0		-		47.9		919.9
Juvederm® Collection		389.8		-		440.8		830.6
Linzess®/Constella®		-		555.9		17.7		573.6
Lumigan®/Ganfort®		217.8		-		295.7		513.5
Bystolic® / Byvalson®		-		432.1		1.6		433.7
Alphagan®/Combigan®		277.7		-		129.3		407.0
Lo Loestrin®		-		383.9		-		383.9
Eye Drops		154.8		-		208.0		362.8
Vraylar®		-		336.6		-		336.6
Alloderm ®		312.4		-		5.5		317.9
Breast Implants		194.8		-		119.6		314.4
Viibryd®/Fetzima®		-		246.9		4.9		251.8
Ozurdex ®		81.7		-		158.1		239.8
Coolsculpting ® Consumables		180.8		-		40.8		221.6
Zenpep®		-		170.5		-		170.5
Carafate ® / Sulcrate ®		-		163.7		2.1		165.8
Armour Thyroid		-		145.4		-		145.4
Canasa®/Salofalk®		-		130.4		13.1		143.5
Asacol®/Delzicol®		-		102.9		35.0		137.9
Viberzi®		-		127.6		0.7		128.3
Coolsculpting ® Systems & Add On Applicators		99.5		-		21.8		121.3
Skin Care		98.4		-		11.6		110.0
Saphris®		-		102.9		-		102.9
Teflaro®		-		98.0		0.6		98.6
Namzaric®		-		93.2		-		93.2
Avycaz®		-		70.0		-		70.0
Rapaflo®		63.0		-		4.6		67.6
Savella®		-		61.4		-		61.4
Namenda®		-		60.3		-		60.3
Aczone®		54.5		-		0.3		54.8
Dalvance®		-		38.8		1.3		40.1
Liletta®		-		36.3		-		36.3
Kybella® / Belkyra®		24.6		-		5.3		29.9
Other		235.3		568.2		291.1		1,094.6
Total segment revenues	$	5,111.5	$	3,925.0	$	2,634.5	$	11,671.0
Corporate revenues								36.7
Total net revenues							$	11,707.7

In connection with the proposed AbbVie Transaction, the Company is actively seeking to divest Zenpep, with any such divestiture contingent on the closing of the AbbVie Transaction.

On July 24, 2019, the Company announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders as a precaution following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provided by the U.S. Food and Drug Administration (“FDA”).

In connection with the voluntary recall, the Company recorded an unfavorable adjustment to operating income of $114.8 million for the nine months ended September 30, 2019. Of this amount, $43.5 million related to estimated customer returns of product previously sold and was recorded as a reduction of net revenues, $61.3 million related to write-offs of inventory and other costs and was recorded in cost of sales, and $10.0 million related to the estimated penalties and costs to undertake the voluntary recall was recorded in selling, general and administrative expense.

NOTE 9 — Inventories

Inventories consist of finished goods held for sale and distribution, raw materials and work-in-process. Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors, which may differ from actual results.

Inventories consisted of the following ($ in millions):

	September 30,		December 31,
	March 31,		December 31,
	2019		2018
	2020		2019
Raw materials	$	~~399~~484.61	$	~~303~~455.2
Work-in-process		~~161~~234.85		~~145~~246.72
Finished goods		~~704~~621.25		~~520~~581.27
		1,265.6		969.1
		1,340.1		1,283.1
Less: inventory reserves		~~182~~140.52		~~122~~150.20
Total Inventories	$	1,~~083~~199.19	$	~~846~~1,133.91

InNOTE 8 — ~~connection~~Accounts ~~with~~Payable ~~the voluntary recall of BIOCELL® textured breast implants~~ and ~~tissue~~Accrued ~~expanders, the Company recorded a $61.3 million charge in Cost of Sales, including $42.1 million to write down inventory held by the Company related to the recall, as of September 30, 2019.~~ Expenses

NOTE 10 — Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following ($ in millions):

	September 30,		December 31,
	March 31,		December 31,
	2019		2018
	2020		2019
Accrued expenses:
Accrued third-party rebates	$	12,~~999~~012.86	$	12,~~832~~001.18
Litigation-related reserves and legal fees		~~881~~352.65		921,250.07

Filing Compare · Allergan plc